



Health Canada

Fees Report - Fiscal Year 2019-20



YOUR HEALTH AND SAFETY... OUR PRIORITY.

Health Canada is the federal department responsible for helping the people of Canada maintain and improve their health. Health Canada is committed to improving the lives of all of Canada's people and to making this country's population among the healthiest in the world as measured by longevity, lifestyle and effective use of the public health care system.

Également disponible en français sous le titre :

Rapport sur les frais - Exercice 2019-2020

To obtain additional information, please contact:

Health Canada

Address Locator 0900C2

Ottawa, ON K1A 0K9

Tel.: 613-957-2991

Toll free: 1-866-225-0709

Fax: 613-941-5366 TTY: 1-800-465-7735

E-mail: hc.publications-publications.sc@canada.ca

© Her Majesty the Queen in Right of Canada, as represented by the Minister of Health, 2020

Publication date: November 2020

This publication may be reproduced for personal or internal use only without permission provided the source is fully acknowledged.

Cat.: H1-9/35E-PDF ISBN: 2562-3346 Pub.: 200211

This document is available on the Government of Canada website at www.canada.ca

This document is available in alternative formats upon request.

Table of contents

Minister's message	5
About this report	
Remissions	7
Overall totals, by fee setting mechanism	7
Totals, by fee grouping, for fees set by act, regulation or fees notice	
Details on each fee set by act, regulation or fees notice	
Fees for Right to Sell Drugs	
Fees for Right to Sell a Licensed Class II, III or IV Medical Device	
Fees for Examination of a Submission — Drugs for Human Use	
Certificate of Supplementary Protection Application Fees	
Fees for Examination of an Application for a Medical Device Licence	
Fees for Examination of a Submission — Drugs for Veterinary Use Only	44
Drug Establishment Licensing Fees	64
Drug Establishment Licensing Fees - Dealer's Licences	70
Medical Device Establishment Licensing Fees	71
Fees to be Paid for the Examination of an Application in Respect of a Pest Con	trol Product
	72
Annual Charge (for a registered Pest Control Product)	112
Fees Charged for Filing a Claim for Exemption under the Hazardous Materials	
Review Act	
Cannabis Fees	114
National Dosimetry Products and Services Fees	118
Master File Fees	
Certificate of Pharmaceutical Product Fee	
Endnotes	122

Minister's message

On behalf of Health Canada, I am pleased to present our report on fees for fiscal year 2019-20, my organization's third annual report under the *Service Fees Act*.

The Service Fees Act provides a modern legislative framework that enables cost-effective delivery of services and, through better reporting to Parliament, improves transparency and oversight.

This year's report includes the revision of the fees with respect to drugs and medical devices. Effective April 1, 2020, where indicated, fees were repealed from the *Financial Administration Act* and set under the authority of the *Food and Drugs Act*. In some instances, new fees were introduced and some fees were discontinued.



Cannabis fees were introduced on October 17, 2018 in support of the legalization, strict regulation and restriction on access to cannabis under the *Cannabis Act*. This year's report is the first time a full year of collections related to cannabis fees is reported. The amount recovered is expected to increase year over year as the legal industry grows, matures and stabilizes. By 2021-22, Health Canada aims to recover as much as 100 percent of annual regulatory costs.

I welcome the increased transparency and oversight that the *Service Fees Act's* reporting regime embodies, and I am fully committed to transitioning my department to this modern framework. I will continue to advance my key mandate priorities through collaboration and evidence-based decision-making that will maintain and improve the health and safety of all Canadians.

The Honourable Patty Hajdu, Minister of Health

About this report

This report, which is tabled under section 20 of the <u>Service Fees Act</u> and section 4.2.8 of the <u>Directive on Charging and Special Financial Authorities</u>ⁱⁱ, contains information about the fees that Health Canada had the authority to set in 2019–20.

Government of Canada departments may set fees for services, licences, permits, products, the use of facilities; for other authorizations of rights or privileges; or to recover, in whole or in part, costs incurred in relation to a regulatory scheme.

For reporting purposes, fees must be categorized under the following three fee setting mechanisms:

- 1. Act, regulation or fees notice
 - An act of Parliament delegates the fee setting authority to a department, minister or Governor in Council.

2. Contract

- Ministers have the authority to enter into contracts, which are usually negotiated between the minister and an individual or organization, and which cover fees and other terms and conditions. In some cases, that authority may also be provided by an act of Parliament.
- 3. Market-rate or auction or both
 - The authority to set these fees is pursuant to an act of Parliament or regulation, and the minister, department or Governor in Council has no control over the fee amount.

This report contains information about all fees that are under Health Canada's authority, including any that are collected by another department.

The information covers fees that are subject to the *Service Fees Act* and fees that are exempted from the *Service Fees Act*.

For fees set by contract, fees set by market-rate, auction or both, the report provides totals only. For fees set by act, regulation or fees notice, it provides totals for fee groupings, as well as detailed information for each fee.

Although the fees that Health Canada charges under the *Access to Information Act* are subject to the *Service Fees Act*, they are not included in this report. Information on Health Canada's access to information fees for 2019–20 can be found in our access to information report, which is posted on our <u>website</u>.

Remissions

A remission is a partial or full return of a fee to a fee payer who paid for a service.

Under the *Service Fees Act*, departments must develop policies for determining whether a service standard has been met and for determining how much of a fee will be remitted to a fee payer if a service standard is not met. This requirement will not take effect until April 1, 2021, therefore this report does not include remissions issued under the *Service Fees Act*.

Under the *Cannabis Act*, the Minister may, by order, remit all or part of any fee fixed by the Minister under subsection 142(1) of the *Cannabis Act*. During 2019-20 the Minister of Health, pursuant to subsection 144(1) of the *Cannabis Act*, via the *Cannabis for Medical Purposes Remission Order*ⁱⁱⁱ, remitted fees paid by certain stakeholders due to an oversight with how the *Cannabis Fees Order* was worded, which resulted in some otherwise eligible licence holders not qualifying for the exemption in the year they were first licenced to sell cannabis for medical purposes. Going forward, this oversight was corrected via the *Order Amending the Cannabis Fees Order (Exemptions — Sale for Medical Purposes)*^{iv}.

Overall totals, by fee setting mechanism

The following table presents the total revenue, cost and remissions for all fees that Health Canada had the authority to set in 2019–20, by fee setting mechanism.

Overall totals for 2019-20, by fee setting mechanism

Fee setting mechanism	Revenue (\$)	Cost (\$)	Remissions (\$)
Fees set by contract *	0	0	Remissions do not apply to fees set by contract.
Fees set by market-rate, auction or both	0	0	Remissions do not apply to fees set by market base, auction or both.
Fees set by act, regulation or fees notice	178,300,057	529,140,037	69,000
Total	178,300,057	529,140,037	69,000

^{*} National Dosimetry Services, Drug Master Files and Certificate of Pharmaceutical Products were reported under "Fees set by contract" in 2018-19. However according to TBS fees that are set and published (ie: in Canada Gazette) are known as "fees set by fees notice" and therefore are to be reported as "Fees set by act, regulation or fees notice".

Totals, by fee grouping, for fees set by act, regulation or fees notice

The following tables present, for each fee grouping, the total revenue, cost and remissions for all fees that Health Canada had the authority to set in 2019–20 that are set by any of the following:

- act
- regulation
- fees notice

A fee grouping is a grouping of all the fees that a department has the authority to set for activities relating to a single business line, directorate or program.

Fees for Right to Sell Drugs: totals for fiscal year 2019-20

Fee grouping	Fees for Right to Sell Drugs	
Revenue (\$)	Cost (\$)	Remissions (\$)
12,376,389	85,021,505	0

Fees for Right to Sell Licensed Class II, III, or IV Medical Devices: totals for fiscal year 2019-20

Fee grouping	Fees for Right to Sell Licensed Class II, III, or IV Medical Devices	
Revenue (\$)	Cost (\$)	Remissions (\$)
8,559,329	26,802,633	0

Fees for Examination of a Submission — Drugs for Human Use: totals for fiscal year 2019-20

1 000 for Examination of a Gabinicolon Brago for framan Good totalo for neodi your 20 to 20			
Fee grouping	Fees for Examination of a Submission — Drugs for Human Use		
Revenue (\$)	Cost (\$)	Remissions (\$)	
50,939,645	129,446,836	0	

Certificate of Supplementary Protection Application Fees: totals for fiscal year 2019-20

Fee grouping	Certificate of Supplementary Protection Application Fees	
Revenue (\$)	Cost (\$)	Remissions (\$)
149,832	420,333	0

Fees for Examination of Medical Device Licence Applications: totals for fiscal year 2019-20

Fee grouping	Fees for Examination of Medical Device Licence Applications	
Revenue (\$)	Cost (\$)	Remissions (\$)
5,613,398	23,779,103	0

Fees for Examination of a Submission — Drugs for Veterinary Use Only: totals for fiscal year 2019-20

Fee grouping	Fees for Examination of a Submission — Drugs for Veterinary Use Only	
Revenue (\$)	Cost (\$)	Remissions (\$)
817,043	10,109,721	0

Drug Establishment Licensing Fees: totals for fiscal year 2019-20

Fee grouping	Drug Establishment Licensing Fees	
Revenue (\$)	Cost (\$)	Remissions (\$)
16,925,045	33,852,458	0

Drug Establishment Licensing Fees - Dealer's Licences: totals for fiscal year 2019-20

Fee grouping	Drug Establishment Licensing Fees - Dealer's Licences	
Revenue (\$)	Cost (\$)	Remissions (\$)
1,140,548	4,032,761	0

Medical Devices Establishment Licensing Fees: totals for fiscal year 2019-20

Fee grouping	Medical Devices Establishment Licensing Fees	
Revenue (\$)	Cost (\$)	Remissions (\$)
9,455,621	12,264,929	0

Fees to be Paid for the Examination of an Application in Respect of a Pest Control Product: totals for fiscal year 2019-20

Fee grouping	Fees to be Paid for the Examination of an Application in Respect of a Pest Control Product	
Revenue (\$)	Cost (\$)	Remissions (\$)
4,632,274	43,284,542	0

Annual Charge (for a registered Pest Control Product): totals for fiscal year 2019-20

Fee grouping	Annual Charge (for a registered Pest Control Product)			
Revenue (\$)	Cost (\$) Remissions (\$)			
8,654,696	33,817,537	0		

Fees Charged for Filing a Claim for Exemption under the Hazardous Materials Information Review Act: totals for fiscal year 2019-20

Fee grouping	Fees Charged for Filing a Claim for Exemption under the Hazardous Materials Information Review Act			
Revenue (\$)	Cost (\$) Remissions (\$)			
511,379	5,496,990	0		

Cannabis Fees: totals for fiscal year 2019-20

Fee grouping	Cannabis Fees	
Revenue (\$)	Cost (\$)	Remissions (\$) (note 1)
50,446,556	110,242,063	69,000

Remitted fees paid by certain stakeholders due to an oversight with how the Cannabis Fees Order was worded, which resulted in some otherwise eligible licence holders not qualifying for the exemption in the year they were first licenced to sell cannabis for medical purposes. (<u>Cannabis for Medical Purposes</u> <u>Remission Order</u>^{jli}).

The following fees are set under the Ministerial Authority to Enter into Contract. Health Canada strives to recover 100% of costs for these services, however since the fees were last set increases to costs have been incurred.

National Dosimetry Products and Services Fees: totals for fiscal year 2019-20

tational 200 motify i roducto and controllor rotation for motify and 2010 20				
Fee grouping	National Dosimetry Products and Services Fees			
Revenue (\$)	Cost (\$) Remissions (\$)			
6,957,396	8,444,108	0		

Master File Fees: totals for fiscal year 2019-20

muotor i no i ocor totalo for nocal your zo io zo				
Fee grouping	Master File Fees			
Revenue (\$)	Cost (\$)	Remissions (\$)		
857,352	1,832,626	0		

Certificate of Pharmaceutical Product Fee: totals for fiscal year 2019-20

Fee grouping	Certificate of Pharmaceutical Product Fee			
Revenue (\$)	Cost (\$) Remissions (\$)			
263,554	291,892 0			

Details on each fee set by act, regulation or fees notice

This section provides detailed information on each fee that Health Canada had the authority to set in 2019–20 and that was set by any of the following:

- act
- regulation
- fees notice

In most cases, the Department does not currently report that revenues are collected at the individual fee level. Health Canada is in the process of implementing changes to the financial system to allow for the reporting of lower level fees in the future.

Fees for Right to Sell Drugs

Health Canada monitors human and veterinary drugs on the Canadian market through post-market surveillance and compliance and enforcement activities. Industry pays an annual fee for the right to maintain and sell human and veterinary drugs in Canada.

	- (D: 144 0 !! D				
Fee grouping		Fees for Right to Sell Drugs				
Fee	Humar	Human Drugs				
Fee-setting	•	Financial Admir	nistration Act (FA	$(A)^{V}$		
authority	•			Medical Devices I	Regulations ^{vi}	
Year fee-setting	1995					
authority was						
introduced						
Last year	2011					
fee-setting						
authority was						
amended						
Service standard	120 da	ys to update the	Drug Product Da	atabase following	receipt of a	
	comple	ete Annual Notific	ation Package			
Performance result	100%	completed on time	е			
Application of Low-						
Materiality Fees	Not su	bject to <i>Service F</i>	ees Act			
Regulations						
Fee		2019–20 fee	2019–20	Fee	Adjusted fee	
		amount (\$)	total fee	adjustment	amount in	
			revenue (\$)	date	2021–22 (\$)	
Human Drugs		1,200	12,376,389	Not	Not	
-9-	applicable, applica					
				fee	fee	
				discontinued	discontinued	
				as of April 1,	as of April 1,	
				2020	2020	

Fee grouping	Fees fo	or Right to Sell Dru	ugs		
Fee	 Human drugs - Disinfectant (item 1) Human drugs - Non-prescription (item 2) Human drugs - Prescription (drug other than one referred to in item 1 or 2) 				
Fee-setting	As at A	April 1, 2020:			
authority	•	Food and Drugs	Act (FDA)vii		
	•	Fees in Respect	of Drugs and M	<u>edical Devices (</u>	Order ^{viii}
Year fee-setting authority was introduced	2019				
Last year fee-setting authority was amended	Not applicable				
Service standard	20 days to update the Drug Product Database following receipt of a complete Annual Notification Package				
Performance result	Not applicable, new fee as of April 1, 2020				
Application of Low- Materiality Fees Regulations	Not subject to Service Fees Act				
Fee	2019–20 fee 2019–20 Fee Adjusted fee amount (\$) total fee adjustment amount in				

Fee	2019–20 fee amount (\$)	2019–20 total fee revenue (\$)	Fee adjustment date	Adjusted fee amount in 2021–22 (\$)
Human drugs - Disinfectant	Not applicable,	Not	April 1, 2021	1,342
(item 1)	new fee as of	applicable,		
Human drugs - Non-	April 1, 2020	new fee as of	April 1, 2021	2,018
prescription (item 2)		April 1, 2020		
Human drugs - Prescription			April 1, 2021	2,749
(drug other than one				
referred to in item 1 or 2)				

Fee grouping	Fees for Right to Sell Drugs					
Fee	Veterinary Drugs					
Fee-setting authority	•	 Financial Administration Act (FAA)^v Authority to Sell Veterinary Drug Fees Regulations^{ix} 				
	As at A	April 1, 2020:	::			
	•	Food and Drugs Fees in Respect		ledical Devices (O <u>rder</u> v ⁱⁱⁱ	
Year fee-setting authority was introduced	1995					
Last year fee-setting authority was amended	2019					
Service standard	comple	ys to update the Dete Annual Notifica April 1, 2020 will	ation Package	tabase following	receipt of a	
Performance result	100%	completed on time)			
Application of Low- Materiality Fees Regulations	Not subject to Service Fees Act					
Fee		2019–20 fee amount (\$)	2019–20 total fee revenue (\$)	Fee adjustment date	Adjusted fee amount in 2021–22 (\$)	
Veterinary Drugs		255.50	Not available at this time	April 1, 2021	367	

Fees for Right to Sell a Licensed Class II, III or IV Medical Device

Health Canada monitors medical devices on the Canadian market through post-market surveillance and compliance and enforcement activities. There is an annual fee for the right to sell a Class II, III, IV medical device.

Fee grouping	Fees for Right to Sell a Licensed Class II, III or IV Medical Device				
Fee	Medical Device Right to Sell (if annual gross revenue medical device sales is less than \$20,000)				
Fee-setting authority	•	<u>Financial Admin</u> <u>Fees in Respect</u>			Regulations ^{vi}
Year fee-setting authority was introduced	1999				
Last year fee-setting authority was amended	2011				
Service standard		s from deadline fo Il Devices License			update the
Performance result	96% cc	mpleted on time			
Application of Low- Materiality Fees Regulations		oject to Service Fe	ees Act		
Fee	2019–20 fee 2019–20 Fee Adjusted f amount (\$) total fee adjustment amount in revenue (\$) date 2021–22 (\$				
Medical Device Right to Sell (if annual gross revenue medical device sales is less than \$20,000)		65	Not available at this time	Not applicable, fee discontinued as of April 1, 2020	Not applicable, fee discontinued as of April 1, 2020

Fee grouping	Fees fo	Fees for Right to Sell a Licensed Class II, III or IV Medical Device				
Fee	Medical Device Right to Sell					
Fee-setting authority	 Financial Administration Act (FAA)^{vvi} Fees in Respect of Drugs and Medical Devices Regulations^{vi} As at April 1, 2020: 					
	•	Food and Drugs Fees in Respect		ledical Devices (Order ^{viii}	
Year fee-setting authority was introduced	1999					
Last year fee-setting authority was amended	2019	2019				
Service standard		s from deadline fo			update the	
Performance result	96% co	ompleted on time				
Application of Low- Materiality Fees Regulations	Not subject to Service Fees Act					
Fee	2019–20 fee 2019–20 Fee Adjusted amount (\$) total fee adjustment amount ir revenue (\$) date 2021–22 (
Medical Device Right t	o Sell	391	Not available at this time	April 1, 2021	381	

Fees for Examination of a Submission — Drugs for Human Use

Before a drug is authorized for sale in Canada, Health Canada reviews it to assess its safety, efficacy and quality. Drug products include prescription and non-prescription pharmaceuticals, biologics, disinfectants and sanitizers with disinfectant claims.

Fee grouping	Fees fo	or Examination of	a Submission –	- Drugs for Hum	an Use
Fee	New A	ctive Substance			
Fee-setting authority	•	 Financial Administration Act (FAA)^{vvi} Fees in Respect of Drugs and Medical Devices Regulations^{vi} 			
	As at A	April 1, 2020:			
	•	Food and Drugs Fees in Respect		ledical Devices (Order ^{viii}
Year fee-setting authority was introduced	1995				
Last year fee-setting authority was amended	2019				
Service standard	New D	rug Submission (I	NDS) - 300 Days	3	
Performance result	NDS -	Pharmaceuticals	(267 Days) Biol	ogics (281 Days)
Application of Low- Materiality Fees Regulations	Not sul	Not subject to Service Fees Act			
Fee		2019–20 fee amount (\$)	2019–20 total fee revenue (\$)	Fee adjustment date	Adjusted fee amount in 2021–22 (\$)
New Active Substance		355,579	Not available at this time	April 1, 2021	437,009

Fee grouping	Fees fo	or Examination of	a Submission –	- Drugs for Hum	an Use	
Fee	Clinica	l or non-clinical da	ata and chemistr	y and manufacti	uring data	
Fee-setting authority	As at A	 Financial Administration Act (FAA)^{vvi} Fees in Respect of Drugs and Medical Devices Regulations^{vi} As at April 1, 2020: Food and Drugs Act (FDA)^{vii} Fees in Respect of Drugs and Medical Devices Order^{viii} 				
Year fee-setting authority was introduced	1995	<u>r ees iir Nespect</u>	Or Drugs and W	edical Devices	<u> Jruer</u>	
Last year fee-setting authority was amended	2019					
Service standard	Supple	rug Submission (Nement to a New Dr Dentification Numb	rug Śubmission	(SNDS) - 300 Da		
Performance result	SNDS	Pharmaceuticals – Pharmaceutical – Pharmaceutical	s (300 Days) Bio	ologics (273 Day	rs)	
Application of Low- Materiality Fees Regulations	Not sul	Not subject to Service Fees Act				
Fee	2019–20 fee 2019–20 Fee Adjusted fe amount (\$) total fee adjustment amount in revenue (\$) date 2021–22 (\$)					
Clinical or non-clinical and chemistry and manufacturing data	data	180,101	Not available at this time	April 1, 2021	224,242	

Fee grouping	Fees fo	or Examination of	a Submission –	- Drugs for Hum	an Use
Fee	Clinical	or non-clinical da	ata only		
Fee-setting authority	As at A	 Financial Administration Act (FAA)^{vvi} Fees in Respect of Drugs and Medical Devices Regulations^{vi} As at April 1, 2020: Food and Drugs Act (FDA)^{vii} Fees in Respect of Drugs and Medical Devices Order^{viii} 			
Year fee-setting authority was introduced	1995				
Last year fee-setting authority was amended	2019				
Service standard	Supple	rug Submission (N ment to a New Dr Ientification Numb	rug Submission	(SNDS) - 300 Da	
Performance result	NDS - SNDS	Pharmaceuticals – Pharmaceutical – Pharmaceuticals	(n/a) Biologics (s (252 Days) Bio	n/a)	
Application of Low- Materiality Fees Regulations	Not sub	oject to <i>Service F</i> o			
Fee		2019–20 fee amount (\$)	2019–20 total fee revenue (\$)	Fee adjustment date	Adjusted fee amount in 2021–22 (\$)
Clinical or non-clinical only	data	84,059	Not available at this time	April 1, 2021	95,796

Fee grouping	Fees fo	or Examination of	a Submission —	- Drugs for Hum	an Use	
Fee	Compa	rative studies				
Fee-setting authority	 Financial Administration Act (FAA)^{vvi} Fees in Respect of Drugs and Medical Devices Regulations^v As at April 1, 2020: 					
	•	Food and Drugs Fees in Respect		ledical Devices	O <u>rder</u> viii	
Year fee-setting authority was introduced	1995					
Last year fee-setting authority was amended	2019	2019				
Service standard	New Di Supple Days Supple	Supplement to a New Drug Submission (SNDS) - 180 Days Drug Identification Number Application (DIN A) - Pharmaceutical - 210				
Performance result	NDS – SANDS SNDS -	 Pharmaceuticals Pharmaceuticals Pharmaceuticals Pharmaceuticals Pharmaceuticals 	(n/a) Biologics (als (161 Days) s (176 Days) Bio	179) blogics (180 Day	/s)	
Application of Low- Materiality Fees Regulations	Not sub	DIN A – Pharmaceuticals (n/a) Biologics (n/a) Not subject to Service Fees Act				
Fee		2019–20 fee amount (\$)	2019–20 total fee revenue (\$)	Fee adjustment date	Adjusted fee amount in 2021–22 (\$)	
Comparative studies		50,808	Not available at this time	April 1, 2021	55,737	

Fee grouping	Fees fo	or Examination of	a Submission —	- Drugs for Hum	an Use
Fee	Chemis	stry and manufact	uring data only		
Fee-setting authority	 Financial Administration Act (FAA)^{vvi} Fees in Respect of Drugs and Medical Devices Regulatio As at April 1, 2020: 				
	•	Food and Drugs Fees in Respect		ledical Devices (O <u>rder</u> v ⁱⁱⁱ
Year fee-setting authority was introduced	1995				
Last year fee-setting authority was amended	2019				
Service standard	New D Supple Days Supple Drug Id	breviated New Drug Submission (ANDS) - 180 Days w Drug Submission (NDS) - 180 Days pplement to an Abbreviated New Drug Submission (SANDS) - 180 ys pplement to a New Drug Submission (SNDS) - 180 Days ug Identification Number Application (DIN A) - 210 Days			
Performance result	NDS – SANDS SNDS	 Pharmaceutical Pharmaceuticals Pharmaceutical Pharmaceutical Pharmaceuticals 	(n/a) als (147 Days) B s (158 Days) Bio	Biologics (n/a) blogics (148 Day	,
Application of Low- Materiality Fees Regulations	Not sul	oject to <i>Service Fe</i>	ees Act		
Fee		2019–20 fee amount (\$)	2019–20 total fee revenue (\$)	Fee adjustment date	Adjusted fee amount in 2021–22 (\$)
Chemistry and manufa data only	cturing	24,023	Not available at this time	April 1, 2021	30,609

Fee grouping	Fees fo	or Examination of	a Submission —	- Drugs for Hum	an Use
Fee	Clinical labellin	l or non-clinical da g	ata only, in supp	ort of safety upg	rades to the
Fee-setting authority	As at A	As at April 1, 2020: • Food and Drugs Act (FDA) ^{vii} • Fees in Respect of Drugs and Medical Devices Order ^{viii}			
Year fee-setting authority was introduced	2019				
Last year fee-setting authority was amended	Not app	Not applicable			
Service standard	120 Da	ıys			
Performance result	Not ap	olicable as new fe	e as of April 1, 2	2020	
Application of Low- Materiality Fees Regulations	Not sub	oject to <i>Service Fe</i>			
Fee		2019–20 fee amount (\$)	2019–20 total fee revenue (\$)	Fee adjustment date	Adjusted fee amount in 2021–22 (\$)
Clinical or non-clinical only, in support of safe upgrades to the labellin	ety	Not applicable as new fee as of April 1, 2020	Not applicable as new fee as of April 1, 2020	April 1, 2021	19,404

Fee grouping	Fees fo	or Examination of	a Submission –	- Drugs for Hum	an Use	
Fee	Publish	Published data only				
Fee-setting authority	• •	Financial Admin Fees in Respect	•		Regulations ^{vi}	
Year fee-setting authority was introduced	1995					
Last year fee-setting authority was amended	2011					
Service standard	Supple Days	Supplement to a new Drug Submission (SNDS) - 300 Days Supplement to an Abbreviated New Drug Submission (SANDS) - 300 Days Drug Identification Number Application (DIN A) - 210 Days				
Performance result	SANDS	– Pharmaceutical S – Pharmaceutic – Pharmaceutical:	als (n/a)	ologics (297 Day	vs)	
Application of Low- Materiality Fees Regulations	Not sul	oject to Service Fo	ees Act			
Fee		2019–20 fee amount (\$)	2019–20 total fee revenue (\$)	Fee adjustment date	Adjusted fee amount in 2021–22 (\$)	
Published data only		19,921	Not available at this time	Not applicable, fee discontinued as of April 1, 2020	Not applicable, fee discontinued as of April 1, 2020	

Fee grouping	Fees fo	or Examination of	a Submission –	- Drugs for Hum	an Use
Fee	Switch	Switch from prescription to non-prescription status			
Fee-setting authority	•	Financial Admin			Regulations ^{vi}
Year fee-setting authority was introduced	1995				
Last year fee-setting authority was amended	2011				
Service standard		rug Submission (I ment to a New Dr			ays
Performance result		Pharmaceuticals (– Pharmaceutical			
Application of Low- Materiality Fees Regulations	Not sul	oject to Service Fo	ees Act		
Fee		2019–20 fee amount (\$)	2019–20 total fee revenue (\$)	Fee adjustment date	Adjusted fee amount in 2021–22 (\$)
Switch from prescription non-prescription status		48,370	Not available at this time	Not applicable, fee discontinued as of April 1, 2020	Not applicable, fee discontinued as of April 1, 2020

Fee grouping	Fees fo	or Examination of	a Submission –	- Drugs for Hum	an Use	
Fee	Labellir	Labelling only				
Fee-setting authority	 Financial Administration Act (FAA)^{vvi} Fees in Respect of Drugs and Medical Devices Regulation As at April 1, 2020: 					
	•	Food and Drugs Fees in Respect		ledical Devices (O <i>rder</i> ^{viii}	
Year fee-setting authority was introduced	1995					
Last year fee-setting authority was amended	2019	2019				
Service standard	Supple Abbrev Supple Days Drug Id	Drug Identification Number Application (DIN A) - 180 Days				
Performance result	SNDS ANDS SANDS	* As of April 2020 will be 120 Days for all types NDS – Pharmaceuticals (54 Days) Biologics (59 Days) SNDS – Pharmaceuticals (50 Days) Biologics (54 Days) ANDS – Pharmaceuticals (39 Days) SANDS – Pharmaceuticals (38 Days) DIN A – Pharmaceuticals (153 Days) Biologics (179 Days)				
Application of Low- Materiality Fees Regulations	Not sub	Not subject to Service Fees Act				
Fee		2019–20 fee amount (\$)	2019–20 total fee revenue (\$)	Fee adjustment date	Adjusted fee amount in 2021–22 (\$)	
Labelling only		3,238	Not available at this time	April 1, 2021	4,320	

Fee grouping	Fees fo	or Examination of	a Submission —	- Drugs for Hum	an Use
Fee	Labellii	Labelling only (generic drugs)			
Fee-setting	As at A	April 1, 2020:			
authority	•	Food and Drugs			
	•	<u>Fees in Respect</u>	of Drugs and M	<u>ledical Devices (</u>	O <u>rder</u> viii
Year fee-setting authority was introduced	2019				
Last year fee-setting authority was amended	Not applicable				
Service standard	120 Da	ays			
Performance result	Not ap	plicable as new fe	e as of April 1, 2	2020	
Application of Low- Materiality Fees Regulations	Not sul	bject to <i>Service Fe</i>	ees Act		
Fee	amount (\$) total fee adjustment amou			Adjusted fee amount in 2021–22 (\$)	
Labelling only (generic drugs)		Not applicable, new fee as of April 1, 2020	Not applicable, new fee as of April 1, 2020	April 1, 2021	2,006

Fee grouping	Fees fo	or Examination of	a Submission —	- Drugs for Hum	an Use	
Fee	Admini	strative submission	n			
Fee-setting authority	 Financial Administration Act (FAA)^{vvi} Fees in Respect of Drugs and Medical Devices Regulations^{vi} As at April 1, 2020: 					
	•	Food and Drugs Fees in Respect		ledical Devices (Order ^{viii}	
Year fee-setting authority was introduced	1995					
Last year fee-setting authority was amended	2019	2019				
Service standard	Abbreviated New Drug Submisson (ANDS) - 45 Days New Drug Submission (NDS) - 45 Days Supplement to a New Drug Submission (SNDS) - 45 Days Supplement to an Abbreviated New Drug Submission (SANDS) - 45 Days Drug Identification Number Application (DIN) - 45 Days Drug Identification Number Application - Disinfectant (DIN Disinfectant) - 45 Days Drug Identification Number Application - Category (DIN Category IV) -					
Performance result	NDS – SNDS SANDS DIN – I DIN Di	ANDS – Pharmaceuticals (22 Days) NDS – Pharmaceuticals (29 Days) Biologics (44 Days) SNDS – Pharmaceuticals (17 Days) SANDS – Pharmaceuticals (17 Days) DIN – Pharmaceuticals (31 Days) Biologics (43 Days) DIN Disinfectant – Pharmaceuticals (32 Days) DIN Category IV – Pharmaceuticals (38 Days)				
Application of Low- Materiality Fees Regulations	Not su	bject to <i>Service Fe</i>	ees Act			
Fee		2019–20 fee amount (\$)	2019–20 total fee revenue (\$)	Fee adjustment date	Adjusted fee amount in 2021–22 (\$)	
Administrative submiss	sion	338	Not available at this time	April 1, 2021	539	

Fee grouping	Fees fo	or Examination of	a Submission –	- Drugs for Hum	an Use
Fee	Disinfe	ctant - full review			
Fee-setting authority	 Financial Administration Act (FAA)^{vvi} Fees in Respect of Drugs and Medical Devices Reg As at April 1, 2020: 				
	•	Food and Drugs Fees in Respect		ledical Devices (<u>Order^{viii}</u>
Year fee-setting authority was introduced	1995				
Last year fee-setting authority was amended	2019				
Service standard	Supple Drug Io 210 Da	Íentification Numb	rug Śubmission (per Application (I	(SNDS) – 300 D Disinfectant 210) (DIN D 210) -
Performance result	SNDS DIN D	Pharmaceuticals – Pharmaceutical 210 – Pharmaceu 180 – Pharmaceu	s (n/a) ticals (204 Days		
Application of Low- Materiality Fees Regulations	Not sul	oject to <i>Service Fe</i>	ees Act		
Fee		2019–20 fee amount (\$)	2019–20 total fee revenue (\$)	Fee adjustment date	Adjusted fee amount in 2021–22 (\$)
Disinfectant - full revie	W	4,480	Not available at this time	April 1, 2021	7,126

Fee grouping	Fees for Examination of a Submission — Drugs for Human Use					
Fee	Labelling only (disinfectants)					
Fee-setting	As at A	April 1, 2020:				
authority	 <u>Food and Drugs Act (FDA)</u>^{vii} 					
	•	 Fees in Respect of Drugs and Medical Devices Order^{viii} 				
Year fee-setting authority was	2019					
introduced						
Last year	Not ap	plicable				
fee-setting						
authority was amended						
Service standard	90 Day	'S				
Performance result	Not ap	plicable as new fe	e as of April 1, 2	2020		
Application of Low- Materiality Fees Regulations	Not subject to Service Fees Act					
Fee 2019–20 fee 2019–20 Fee Adjusted amount (\$) total fee adjustment amount in					Adjusted fee amount in 2021–22 (\$)	
Labelling only (disinfectants)		Not applicable, new fee as of April 1, 2020	Not applicable, new fee as of April 1, 2020	April 1, 2021	2,502	

Fee grouping		Fees for Examination of a Submission — Drugs for Human Use				
Fee	Drug ic	lentification numb	er application –	labelling standa	rds	
Fee-setting authority	•	Financial Admin Fees in Respect			Regulations ^{vi}	
	As at April 1, 2020:					
	•	 Food and Drug Act (FDA)^{vii} 				
	•	Fees in Respect	of Drugs and M	<u>ledical Devices (</u>	Order ^{viii}	
Year fee-setting authority was introduced	1995					
Last year fee-setting authority was amended	2019	2019				
Service standard	Drug lo Days Drug lo	Drug Identification Number Application (DIN A) - 45 Days Drug Identification Number Application - Disinifectant (DIN D) - 45 Days Drug Identification Number Application - Category IV (DIN F) - 45 Days * As of April 2020 it will be 60 Days for all types				
Performance result	DIN D	DIN A – Pharmaceuticals (40 Days) DIN D – Pharmaceuticals (38 Days) DIN F – Pharmaceuticals (36 Days)				
Application of Low- Materiality Fees Regulations		Not subject to Service Fees Act				
Fee	amount (\$) total fee adjustment amount				Adjusted fee amount in 2021–22 (\$)	
Drug identification number application – labelling standards		1,797	Not available at this time	April 1, 2021	1,613	

Certificate of Supplementary Protection Application Fees

In agreeing to provisionally apply the Canada-European Union Comprehensive Economic and Trade Agreement (CETA), Canada has committed to provide up to two years of sui generis (of its own kind) protection for new pharmaceutical products protected by an eligible patent, from the expiry of the patent. Canada has implemented this commitment by introducing Certificates of Supplementary Protection (CSPs) for medicinal ingredients, applicable for Canadian pharmaceuticals, biologics and veterinary drugs.

Fee grouping	Certific	Certificate of Supplementary Protection Application Fees				
Fee	Certificate of Supplementary Protection Application Fees					
Fee-setting	•	Patent Actx				
authority	•	Certificate of S	Supplementary Pro	otection Regulati	ions ^{xi}	
Year fee-setting	2017					
authority was						
introduced						
Last year	Not ap	plicable				
fee-setting authority was						
amended						
Service standard	60 day	s for the first elig	gibility decision			
Performance result	•	ssued within 60				
Application of Low-			-			
Materiality Fees	Not sul	bject to Service	Fees Act			
Regulations						
Fee	2019–20 fee 2019–20 total Fee Adjusted fee					
	amount (\$) fee revenue adjustment amount in					
	(\$) date 2021–22 (\$)					
Certificate of Supplementary		9,376	149,832	April 1, 2021	9,756	
Protection Application Fees						

Fees for Examination of an Application for a Medical Device Licence

The Medical Device Licence Application Fees apply only to Class II, III and IV medical device licence applications. The following types of medical devices are exempt from medical device licensing and therefore no fees apply: Class I medical devices; custom-made medical devices; medical devices for special access; medical devices for investigational testing involving human subjects.

Fee grouping	Fees fo	Fees for Examination of an Application for a Medical Device Licence				
Fee	Applications for Class II licence					
Fee-setting authority	 Financial Administration Act (FAA)^v Fees in Respect of Drugs and Medical Devices Regulations^{vi} 					
	As at A	April 1, 2020:				
	•	 Food and Drugs Act (FDA)^{vii} Fees in Respect of Drugs and Medical Devices Order^{viii} 				
Year fee-setting authority was introduced	1998					
Last year fee-setting authority was amended	2019					
Service standard	15 Day	s to complete Re	view 1			
Performance result	9 Days	to complete Revi	iew 1			
Application of Low- Materiality Fees Regulations	Not subject to Service Fees Act					
Fee		2019–20 fee amount (\$)	2019–20 total fee revenue (\$)	Fee adjustment date	Adjusted fee amount in 2021–22 (\$)	
Applications for Class licence		414	Not available at this time	April 1, 2021	478	

Fee grouping	Fees for Examination of an Application for a Medical Device Licence					
Fee	Applications for Class II licence amendment					
Fee-setting	As at A	April 1, 2020:				
authority	Food and Drugs Act (FDA) ^{vii}					
	•	 <u>Fees in Respect of Drugs and Medical Devices Order</u>^{viii} 				
Year fee-setting authority was introduced	2019	2019				
Last year fee-setting authority was amended	Not applicable					
Service standard	15 Day	s to complete Re	view 1			
Performance result	Not ap	plicable, new fee	as of April 1, 202	20		
Application of Low- Materiality Fees Regulations	Not sub	Not subject to Service Fees Act				
Fee	2019–20 fee amount (\$) Fee Adjusted fee adjustment amount in revenue (\$) date 2021–22 (\$)					
Applications for Class II licence amendment		Not applicable, new fee as of April 1, 2020	Not applicable, new fee as of April 1, 2020	April 1, 2021	272	

Fee grouping	Fees for Examination of an Application for a Medical Device Licence					
Fee	Applications for Class III licence					
Fee-setting authority	•	 Financial Administration Act (FAA)^v Fees in Respect of Drugs and Medical Devices Regulations^{vi} 				
	As at A	April 1, 2020:				
	•	Food and Drugs	Act (FDA) ^{vii}			
	•	<u>Fees in Respect</u>	t of Drugs and M	<u>ledical Devices (</u>	<u>Order^{viii}</u>	
Year fee-setting authority was introduced	1998					
Last year fee-setting authority was amended	2019	2019				
Service standard	60 Day	s to complete Re	view 1			
Performance result	45 Day	s to complete Re	view 1			
Application of Low- Materiality Fees Regulations	Not subject to Service Fees Act					
Fee	2019–20 fee 2019–20 Fee Adjusted fee adjustment amount in revenue (\$) date 2021–22 (\$)					
Applications for Class licence	III	5,922	Not available at this time	April 1, 2021	8,895	

Fee grouping	Fees fo	Fees for Examination of an Application for a Medical Device Licence				
Fee	Applications for Class III licence (near patient)					
Fee-setting authority	•	 <u>Financial Administration Act (FAA)</u>^v <u>Fees in Respect of Drugs and Medical Devices Regulations</u>^{vi} 				
	As at A	April 1, 2020:				
	•	Food and Drugs Act (FDA) ^{vii}				
	•	<u>Fees in Respect</u>	t of Drugs and M	<u>ledical Devices (</u>	<u>Order^{viii}</u>	
Year fee-setting authority was introduced	1998					
Last year fee-setting authority was amended	2019					
Service standard	60 Day	s to complete Re	view 1			
Performance result	Not ap	plicable				
Application of Low- Materiality Fees Regulations	Not subject to Service Fees Act					
Fee	2019–20 fee 2019–20 Fee Adjusted fee amount (\$) total fee adjustment amount in revenue (\$) date 2021–22 (\$)					
Applications for Class licence (near patient)	III	10,079	Not available at this time	April 1, 2021	16,032	

Fee grouping	Fees fo	Fees for Examination of an Application for a Medical Device Licence				
Fee	Applications for Class III licence amendment - changes in manufacturing					
Fee-setting authority	 Financial Administration Act (FAA)^v Fees in Respect of Drugs and Medical Devices Regulations^{vi} As at April 1, 2020: Food and Drugs Act (FDA)^{vii} 					
	•	Fees in Respect	t of Drugs and M	<u>ledical Devices (</u>	<u>Order^{viii}</u>	
Year fee-setting authority was introduced	1998	1998				
Last year fee-setting authority was amended	2019	2019				
Service standard	60 Day	s to complete Re	view 1			
Performance result	41 Day	s to complete Re	view 1			
Application of Low- Materiality Fees Regulations	Not sul	Not subject to Service Fees Act				
Fee	2019–20 fee amount (\$) total fee adjustment amount in revenue (\$) date 2021–22 (\$)					
Applications for Class III licence amendment - changes in manufacturing		1,492	Not available at this time	April 1, 2021	2,375	

Fee grouping	Fees fo	or Examination of	an Application f	or a Medical Dev	vice Licence
Fee		Applications for Class III licence amendment - significant changes not related to manufacturing			
Fee-setting authority	•	<u>Financial Admin</u> <u>Fees in Respect</u>			Regulations ^{vi}
	As at A	April 1, 2020:			
	•	Food and Drugs	Act (FDA)vii		
	•	Fees in Respect	of Drugs and M	<u>ledical Devices (</u>	<u>Order</u> ^{viii}
Year fee-setting authority was introduced	1998	1998			
Last year fee-setting authority was amended	2019				
Service standard	60 Day	s to complete Re	view 1		
Performance result	44 Day	s to complete Re	view 1		
Application of Low- Materiality Fees Regulations	Not sul	Not subject to Service Fees Act			
Fee	Fee		2019–20 total fee revenue (\$)	Fee adjustment date	Adjusted fee amount in 2021–22 (\$)
Applications for Class III licence amendment - significant changes not related to manufacturing		5,546	Not available at this time	April 1, 2021	7,543

Fee grouping	Fees fo	or Examination of	an Application fo	or a Medical Dev	vice Licence
Fee	Applications for Class IV licence				
Fee-setting authority	•	 <u>Financial Administration Act (FAA)</u>^v Fees in Respect of Drugs and Medical Devices Regulations^{vi} 			
	As at A	April 1, 2020:			
	•	Food and Drugs	: Act (FDA) ^{vii}		
	•	Fees in Respect	t of Drugs and M	<u>ledical Devices (</u>	<u>Order</u> ^{viii}
Year fee-setting authority was introduced	1998				
Last year fee-setting authority was amended	2019				
Service standard	75 Day	s to complete Re	view 1		
Performance result	64 Day	s to complete Re	view 1		
Application of Low- Materiality Fees Regulations	Not subject to Service Fees Act				
Fee		2019–20 fee amount (\$)	2019–20 total fee revenue (\$)	Fee adjustment date	Adjusted fee amount in 2021–22 (\$)
Applications for Class licence	IV	13,770	Not available at this time	April 1, 2021	24,699

Fee grouping	Fees fo	or Examination of	an Application fo	or a Medical Dev	vice Licence
Fee		Class IV - Licence Application (Devices that contain Human- Animal Tissue)			
Fee-setting authority	• •	Financial Admin Fees in Respect	•	•	Regulations ^{vi}
Year fee-setting authority was introduced	1998				
Last year fee-setting authority was amended	2011	2011			
Service standard	75 Day	s to complete Rev	view 1		
Performance result	68 Day	s to complete Re	view 1		
Application of Low- Materiality Fees Regulations	Not sub	oject to <i>Service F</i> e	ees Act		
Fee		2019–20 fee amount (\$)	2019–20 total fee revenue (\$)	Fee adjustment date	Adjusted fee amount in 2021–22 (\$)
Class IV - Licence Application (Devices that contain Human- Animal Tissue)		12,846	Not available at this time	Not applicable, fee discontinued as of April 1, 2020	Not applicable, fee discontinued as of April 1, 2020

Fee grouping	Fees for Examination of an Application for a Medical Device Licence				
Fee	Class I	Class IV - Licence Application (Near patient In Vitro Diagnostic Device)			
Fee-setting authority	• •	Financial Admin Fees in Respect			Regulations ^{vi}
Year fee-setting authority was introduced	1998				
Last year fee-setting authority was amended	2011				
Service standard	75 Day	s to complete Re	view 1		
Performance result	Not ap	plicable			
Application of Low- Materiality Fees Regulations	Not su	bject to <i>Service F</i> o	ees Act		
Fee		2019–20 fee amount (\$)	2019–20 total fee revenue (\$)	Fee adjustment date	Adjusted fee amount in 2021–22 (\$)
Class IV - Licence Application (Near patient In Vitro Diagnostic Device)		23,473	Not available at this time	Not applicable, fee discontinued as of April 1, 2020	Not applicable, fee discontinued as of April 1, 2020

Fee grouping	Fees fo	or Examination of	an Application fo	or a Medical Dev	vice Licence
Fee		atons for Class IV acturing	licence amendn	nent - changes i	n
Fee-setting authority	 Financial Administration Act (FAA)^v Fees in Respect of Drugs and Medical Devices Regulations^{vi} As at April 1, 2020: Food and Drugs Act (FDA)^{vii} Fees in Respect of Drugs and Medical Devices Order^{viii} 				
Year fee-setting authority was introduced	1998				
Last year fee-setting authority was amended	2019				
Service standard	75 Day	s to complete Re	view 1		
Performance result	41 Day	s to complete Re	view 1		
Application of Low- Materiality Fees Regulations	Not sul	Not subject to Service Fees Act			
Fee		2019–20 fee amount (\$)	2019–20 total fee revenue (\$)	Fee adjustment date	Adjusted fee amount in 2021–22 (\$)
Applicatons for Class IV licence amendment - changes in manufacturing		1,492	Not available at this time	April 1, 2021	2,375

Fee grouping	Fees fo	or Examination of	an Application f	or a Medical Dev	vice Licence
Fee		Applications for Class IV licence amendment - significange changes not related to manufacturing			
Fee-setting authority	• • As at A	 <u>Financial Administration Act (FAA)</u>^v <u>Fees in Respect of Drugs and Medical Devices Regulations</u>^{vi} As at April 1, 2020:			
	•	Food and Drugs Fees in Respect		ledical Devices (Order ^{viii}
Year fee-setting authority was introduced	1998				
Last year fee-setting authority was amended	2019	2019			
Service standard	75 Day	s to complete Re	view 1		
Performance result	54 Day	s to complete Re	view 1		
Application of Low- Materiality Fees Regulations	Not sul	oject to <i>Service Fe</i>	ees Act		
Fee		2019–20 fee amount (\$)	2019–20 total fee revenue (\$)	Fee adjustment date	Adjusted fee amount in 2021–22 (\$)
Applications for Class IV licence amendment - significange changes not related to manufacturing		6,319	Not available at this time	April 1, 2021	9,964

Fee grouping		Fees for Examination of an Application for a Medical Device Licence Applications for Class II, III or IV licence or licence amendment -			
Fee		itions for Class II, label medical dev		or licence amen	dment -
Fee-setting authority	As at A	April 1, 2020:			
authority	 Food and Drugs Act (FDA)^{vii} Fees in Respect of Drugs and Medical Devices Order^{viii} 				
Year fee-setting authority was introduced	2019	2019			
Last year fee-setting authority was amended	Not app	Not applicable			
Service standard	15 Day	s to complete Rev	view 1		
Performance result	Not app	olicable, new fee a	as of April 1, 202	20	
Application of Low- Materiality Fees Regulations	Not sub	oject to <i>Service Fe</i>	ees Act		
Fee		2019–20 fee amount (\$)	2019–20 total fee revenue (\$)	Fee adjustment date	Adjusted fee amount in 2021–22 (\$)
Applications for Class II, III or IV licence or licence amendment - private label medical device		Not applicable, new fee as of April 1, 2020	Not applicable, new fee as of April 1, 2020	April 1, 2021	147

Fees for Examination of a Submission — Drugs for Veterinary Use Only

Before a veterinary drug is authorized for sale in Canada, Health Canada reviews it to assess it efficacy and safety in the intended species as well as human safety. Fees are calculated on a component basis.

Fee grouping	Fees fo	or Examination of	a Submission –	- Drugs for Vete	rinary Use
Fee		Drug Identification Number			
Fee-setting authority	 Financial Administration Act (FAA)^v Veterinary Drug Evaluation Fees Regulations^{xii} As at April 1, 2020: 				
	•	Food and Drugs	Act (FDA) ^{vii}		
	•		t of Drugs and M	ledical Devices	O <u>rder</u> ^{viii}
Year fee-setting authority was introduced	1996				
Last year fee-setting authority was amended	2019				
Service standard	120 Da	ays to complete R	eview 1		
Performance result	78 Day	s to complete Re	view 1		
Application of Low- Materiality Fees Regulations	Not su	bject to <i>Service F</i>			
Fee		2019–20 fee amount (\$)	2019–20 total fee revenue (\$)	Fee adjustment date	Adjusted fee amount in 2021–22 (\$)
Information, other than that referred to in item 2, to support an application for a number, including the submission of labelling material for a second review, if required		735.84	Not available at this time	April 1, 2021	1,146
Published references of other data	Published references or other data		Not available at this time	April 1, 2021	797
Documentation to support change of manufacture change to the name of manufacturer or a characturer or a characture brand name of a different characteristics.	er, a a nge to	255.50	Not available at this time	April 1, 2021	400

Fee grouping	Fees fo	Fees for Examination of a Submission — Drugs for Veterinary Use Only				
Fee	Notifica	ation – veterinary	health product			
Fee-setting authority	As at A	As at April 1, 2020: • Food and Drugs Act (FDA) ^{vii} • Fees in Respect of Drugs and Medical Devices Order ^{viii}				
Year fee-setting authority was introduced	2019					
Last year fee-setting authority was amended	Not ap	Not applicable				
Service standard	30 Day	s to process notifi	ication			
Performance result	Not ap	plicable, as this is	a new fee as of	April 1, 2020		
Application of Low- Materiality Fees Regulations	Not sub	oject to <i>Service Fe</i>	ees Act			
Fee		2019–20 fee amount (\$)	2019–20 total fee revenue (\$)	Fee adjustment date	Adjusted fee amount in 2021–22 (\$)	
Information contained in a notification filed under subsection C.01.615(1) of the Food and Drug Regulations in respect of a veterinary health product		Not applicable, as this is a new fee as of April 1, 2020	Not applicable, as this is a new fee as of April 1, 2020	April 1, 2021	486	

Fee grouping	Fees for Examination of a Submission — Drugs for Veterinary Use Only			
Fee	New drug submission			
Fee-setting authority	 <u>Financial Administration Act (FAA)</u>^v <u>Veterinary Drug Evaluation Fees Regulations</u>^{xii} As at April 1, 2020:			
	 <u>Food and Drugs Act (FDA)</u>^{vii} 			
	 <u>Fees in Respect of Drugs and Medical Devices Order</u>viii 			
Year fee-setting authority was introduced	1996			
Last year fee-setting authority was amended	2019			
Service standard	 300 Days to complete Review 1 (other than Administrative New Drug Submission (NDS)) 90 Days to complete review for Administrative New Drug Submission (NDS) 			
Performance result	 194 Days to complete Review 1 (other than Administrative NDS) 28 Days to complete review for Administrative NDS 			
Application of Low- Materiality Fees Regulations	Not subject to Service Fees Act			

Fee	2019–20 fee amount (\$)	2019–20 total fee revenue (\$)	Fee adjustment date	Adjusted fee amount in 2021–22 (\$)
Efficacy and safety data (in the intended species) to support a single route of administration, dosage form and indication in one animal species. (In the case of an antiparasitic drug, several indications in one food animal species.)	16,331.56	Not available at this time	April 1, 2021	25,419
Efficacy and safety data (in the intended species) to support a single route of administration and dosage form for an antiparasitic drug in one non-food animal species	9,892.96	Not available at this time	April 1, 2021	15,398

Fee	2019–20 fee amount (\$)	2019–20 total fee revenue (\$)	Fee adjustment date	Adjusted fee amount in 2021–22 (\$)
Efficacy and safety data (in the intended species) to support a single route of administration, dosage form and indication in two animal species, or a single route of administration, dosage form and two indications in one animal species	23,751.28	Not available at this time	April 1, 2021	36,966
Efficacy and safety data (in the intended species) to support a growth promotion or production enhancement indication in one animal species	32,162.34	Not available at this time	April 1, 2021	50,057
Comparative (pharmacodynamics, clinical or bioavailability) data to support an additional route of administration	2,963.80	Not available at this time	April 1, 2021	4,614
Comparative (pharmacodynamics, clinical or bioavailability) data to support each additional strength	490.56	Not available at this time	April 1, 2021	764
For food-producing animals, toxicity, metabolism and residue depletion studies to establish an acceptable daily intake with a safety factor of 1,000, a maximum residue limit and a withdrawal period for a single dosage form, dosage and route of administration in one species	22,269.38	Not available at this time	April 1, 2021	34,660
For food-producing animals, toxicity, metabolism and residue depletion studies to establish an acceptable daily intake with a safety factor of less than 1,000, a maximum residue limit and a withdrawal period for a single dosage form, dosage and route of administration in one species	29,689.10	Not available at this time	April 1, 2021	46,208

Fee	2019–20 fee amount (\$)	2019–20 total fee revenue (\$)	Fee adjustment date	Adjusted fee amount in 2021–22 (\$)
For food-producing animals, residue depletion studies to establish a withdrawal period for an additional dosage form, dosage or route of administration	2,963.80	Not available at this time	April 1, 2021	4,614
For food-producing animals (once an acceptable daily intake with a safety factor of 1,000 or less has been established), metabolism and residue depletion studies to establish a maximum residue limit and a withdrawal period for a single dosage form, dosage and route of administration in an additional species	14,839.44	Not available at this time	April 1, 2021	23,096
Chemistry and manufacturing data for a non-compendial medicinal ingredient of a drug	4,946.48	Not available at this time	April 1, 2021	7,700
Chemistry and manufacturing data to support one strength of a single dosage form	4,946.48	Not available at this time	April 1, 2021	7,700
Chemistry and manufacturing data to support an additional strength of a single dosage form submitted at the same time as the above item	2,473.24	Not available at this time	April 1, 2021	3,851
Documentation to support a change of manufacturer	255.50	Not available at this time	April 1, 2021	400

Fee grouping	Fees for Examination of a Submission — Drugs for Veterinary Use Only		
Fee	Supplement to a new drug submission		
Fee-setting authority	 <u>Financial Administration Act (FAA)</u>^v <u>Veterinary Drug Evaluation Fees Regulations</u>^{xii} 		
	As at April 1, 2020:		
	 <u>Food and Drugs Act (FDA)</u>^{vii} 		
	 Fees in Respect of Drugs and Medical Devices Order Viii 		
Year fee-setting authority was introduced	1996		
Last year fee-setting authority was amended	2019		
Service standard	240 Days to complete Review 1		
Performance result	147 Days to complete Review 1		
Application of Low- Materiality Fees Regulations	Not subject to Service Fees Act		
Fee	2019–20 fee 2019–20 Fee Adjusted fee		

Fee	2019–20 fee amount (\$)	2019–20 total fee revenue (\$)	Fee adjustment date	Adjusted fee amount in 2021–22 (\$)
Efficacy data to support an additional indication in one animal species	12,866.98	Not available at this time	April 1, 2021	20,027
Efficacy and safety data (in the intended species) to support a single route of administration and dosage form for an antiparasitic drug in one non-food animal species	9,892.96	Not available at this time	April 1, 2021	15,398
Efficacy and safety data (in the intended species) to support an indication in another animal species	16,331.56	Not available at this time	April 1, 2021	25,419
Efficacy and safety data (in the intended species) to support a single route of administration, dosage form and indication in two animal species, or a single route of administration and dosage form and two indications in one animal species.	23,751.28	Not available at this time	April 1, 2021	36,966

Fee	2019–20 fee amount (\$)	2019–20 total fee revenue (\$)	Fee adjustment date	Adjusted fee amount in 2021–22 (\$)
Efficacy and safety data (in the intended species) to support a growth promotion or production enhancement indication in one animal species	32,162.34	Not available at this time	April 1, 2021	50,057
Efficacy and safety data (in the intended species) to support the concurrent use of two drugs approved for the same animal species	7,910.28	Not available at this time	April 1, 2021	12,312
Comparative (pharmacodynamics, clinical or bioavailability) data to support an additional route of administration	2,963.80	Not available at this time	April 1, 2021	4,614
Comparative (pharmacodynamics, clinical or bioavailability) data to support each additional strength	490.56	Not available at this time	April 1, 2021	764
For food-producing animals, residue depletion studies to establish a new withdrawal period for a change in the dosage or route of administration of an approved dosage form in one species	2,963.80	Not available at this time	April 1, 2021	4,614
For food-producing animals, metabolism and residue depletion studies to establish a maximum residue limit and a withdrawal period for a single dosage and route of administration of an approved dosage form in an additional species	14,839.44	Not available at this time	April 1, 2021	23,096
For food-producing animals, toxicity studies to support a change of an established acceptable daily intake, maximum residue limit and withdrawal period	7,419.72	Not available at this time	April 1, 2021	11,548

Fee	2019–20 fee amount (\$)	2019–20 total fee revenue (\$)	Fee adjustment date	Adjusted fee amount in 2021–22 (\$)
For the concurrent use of two drugs in a species of food-producing animals, residue depletion studies to determine if an extension to existing withdrawal periods is required	5,937.82	Not available at this time	April 1, 2021	9,243
Chemistry and manufacturing data to support a change in the source of a medicinal ingredient or its manufacturing process	4,946.48	Not available at this time	April 1, 2021	7,700
Chemistry and manufacturing data to support a change in formulation or dosage form	2,473.24	Not available at this time	April 1, 2021	3,851
Chemistry and manufacturing data to support a change in packaging or in the sterilization process	1,972.46	Not available at this time	April 1, 2021	3,072
Chemistry and manufacturing data to support an extension of the expiry dating	1,481.90	Not available at this time	April 1, 2021	2,309
Chemistry and manufacturing data to support the concurrent use of two drugs	1,481.90	Not available at this time	April 1, 2021	2,309
Chemistry and manufacturing data to support a change in the manufacturing site for parenteral dosage forms	490.56	Not available at this time	April 1, 2021	764
Documentation to support a change to the name of a manufacturer or the brand name of a drug	255.50	Not available at this time	April 1, 2021	400

Fee grouping	Fees fo	Fees for Examination of a Submission — Drugs for Veterinary Use Only			
Fee	Abbrev	riated new drug su	ubmission		
Fee-setting authority	• • As at A	 Financial Administration Act (FAA)^v Veterinary Drug Evaluation Fees Regulations^{xii} As at April 1, 2020:			
	•	Food and Drugs	Act (FDA) ^{vii}		
	•	Fees in Respect		ledical Devices (Order ^{viii}
Year fee-setting authority was introduced	1996		<u> </u>		
Last year fee-setting authority was amended	2019				
Service standard	300 Da	300 Days to complete Review 1			
Performance result	270 Days to complete Review 1				
Application of Low- Materiality Fees Regulations	Not subject to Service Fees Act				
Fee	amount (\$) total fee adjustment amount in				Adjusted fee amount in 2021–22 (\$)
Comparative	2,963.80 Not available April 1, 2021 4,614				4,614

Fee	2019–20 fee amount (\$)	2019–20 total fee revenue (\$)	Fee adjustment date	Adjusted fee amount in 2021–22 (\$)
Comparative (pharmacodynamics, clinical or bioavailability) data to support a single route of administration and dosage form.	2,963.80	Not available at this time	April 1, 2021	4,614
For food-producing animals, residue depletion studies to confirm that the withdrawal period(s) for each species falls within the conditions of use for the Canadian reference product.	2,963.80	Not available at this time	April 1, 2021	4,614
Chemistry and manufacturing data for a non-compendial medicinal ingredient of a drug.	4,946.48	Not available at this time	April 1, 2021	7,700
Chemistry and manufacturing data to support a single dosage form.	4,946.48	Not available at this time	April 1, 2021	7,700

Fee	2019–20 fee amount (\$)	2019–20 total fee revenue (\$)	Fee adjustment date	Adjusted fee amount in 2021–22 (\$)
Documentation to support (a) a change of manufacturer, in the case of an abbreviated new drug submission; or (b) a change to the name of a manufacturer or the brand name of a drug, in the case of a supplement to an abbreviated new drug submission.	255.50	Not available at this time	April 1, 2021	400

Fee grouping	Fees fo	Fees for Examination of a Submission — Drugs for Veterinary Use Only				
Fee	Supple	ment to an abbre	viated new drug	submission		
Fee-setting authority	•	 <u>Financial Administration Act (FAA)</u>^v <u>Veterinary Drug Evaluation Fees Regulations</u>^{xii} 				
	As at A	April 1, 2020:				
	•	Food and Drugs	: Act (FDA) ^{vii}			
	•	Fees in Respect	t of Drugs and M	ledical Devices	<u>Order</u> ^{viii}	
Year fee-setting authority was introduced	1996					
Last year fee-setting authority was amended	2019					
Service standard	240 Da	ays to complete R	eview 1			
Performance result	180 Days to complete Review 1					
Application of Low- Materiality Fees Regulations	Not subject to Service Fees Act					
Fee		2019–20 fee	2019–20 total fee	Fee	Adjusted fee	

Fee	2019–20 fee amount (\$)	2019–20 total fee revenue (\$)	Fee adjustment date	Adjusted fee amount in 2021–22 (\$)
Comparative (pharmacodynamics, clinical or bioavailability) data to support a single route of administration and dosage form.	2,963.80	Not available at this time	April 1, 2021	4,614
For food-producing animals, residue depletion studies to confirm that the withdrawal period(s) for each species falls within the conditions of use for the Canadian reference product.	2,963.80	Not available at this time	April 1, 2021	4,614
Chemistry and manufacturing data for a non-compendial medicinal ingredient of a drug.	4,946.48	Not available at this time	April 1, 2021	7,700
Chemistry and manufacturing data to support a single dosage form.	4,946.48	Not available at this time	April 1, 2021	7,700

Fee	2019–20 fee amount (\$)	2019–20 total fee revenue (\$)	Fee adjustment date	Adjusted fee amount in 2021–22 (\$)
Documentation to support (a) a change of manufacturer, in the case of an abbreviated new drug submission; or (b) a change to the name of a manufacturer or the brand name of a drug, in the case of a supplement to an abbreviated new drug submission.	255.50	Not available at this time	April 1, 2021	400

Fee grouping	Fees for Examination of a Submission — Drugs for Veterinary Use Only
Fee	Preclinical new drug submission
Fee-setting authority	Financial Administration Act (FAA) ^v Veterinary Drug Evaluation Fees Regulations ^{xii} Ac at April 1, 2020:
	As at April 1, 2020:
	 <u>Food and Drugs Act (FDA)</u>^{vii} <u>Fees in Respect of Drugs and Medical Devices Order</u>^{viii}
Year fee-setting authority was introduced	1996
Last year fee-setting authority was amended	2019
Service standard	60 Days to review application
Performance result	n/a for 2019-20
Application of Low- Materiality Fees Regulations	Not subject to Service Fees Act

Fee	2019–20 fee amount (\$)	2019–20 total fee revenue (\$)	Fee adjustment date	Adjusted fee amount in 2021–22 (\$)
Efficacy and safety (in the intended species) and protocol to support the conduct of clinical studies relative to a single dose form, route of administration and indication in one species	4,946.48	Not available at this time	April 1, 2021	7,700
Efficacy data and protocol to support the conduct of clinical studies relative to a single route of administration and indication with a dosage form for which a notice of compliance has been issued for use in the species to be treated	3,955.14	Not available at this time	April 1, 2021	6,157

Fee	2019–20 fee amount (\$)	2019–20 total fee revenue (\$)	Fee adjustment date	Adjusted fee amount in 2021–22 (\$)
For food-producing animals, toxicity, metabolism and residue depletion studies to establish a temporary acceptable daily intake, a maximum residue limit and a withdrawal period for a single dosage form, dosage and route of administration in one species	14,839.44	Not available at this time	April 1, 2021	23,096
For food-producing animals, toxicity, metabolism and residue depletion studies to establish an acceptable daily intake with a safety factor of 1,000, a maximum residue limit and a withdrawal period for a single dosage form, dosage and route of administration in one species	22,269.38	Not available at this time	April 1, 2021	34,660
For food-producing animals, toxicity, metabolism and residue depletion studies to establish an acceptable daily intake with a safety factor of less than 1,000, a maximum residue limit and a withdrawal period for a single dosage form, dosage and route of administration in one species	29,689.10	Not available at this time	April 1, 2021	46,208
For food-producing animals (once an acceptable daily intake with a safety factor of 1,000 or less has been established), metabolism studies to establish a withdrawal period for a single dosage form, dosage and route of administration in an additional species	7,419.72	Not available at this time	April 1, 2021	11,548
Chemistry and manufacturing data to support a single dosage form containing a non-compendial medicinal ingredient	4,946.48	Not available at this time	April 1, 2021	7,700

Fee	2019–20 fee amount (\$)	2019–20 total fee revenue (\$)	Fee adjustment date	Adjusted fee amount in 2021–22 (\$)
Chemistry and manufacturing data to support a single dosage form containing a compendial medicinal ingredient	2,473.24	Not available at this time	April 1, 2021	3,851

Fee grouping	Fees for Examination of a Submission — Drugs for Veterinary Use Only					
Fee	Sale of	Sale of new drug for emergency treatment				
Fee-setting authority	• • As at A	 Financial Administration Act (FAA)^v Veterinary Drug Evaluation Fees Regulations^{xii} As at April 1, 2020:				
	•	Food and Drugs		ledical Devices	Order ^{viii}	
Year fee-setting authority was introduced	1996	Fees in Respect of Drugs and Medical Devices Order 1996				
Last year fee-setting authority was amended	2019					
Service standard	2 busir	ness days to revie	w application			
Performance result	<2 bus	iness days to revi	ew application			
Application of Low- Materiality Fees Regulations	Not su	bject to Service F	ees Act			
Fee		2019–20 fee amount (\$)	2019–20 total fee revenue (\$)	Fee adjustment date	Adjusted fee amount in 2021–22 (\$)	
Information to support the sale of a drug to be used in the emergency treatment of a non-food-producing animal		51.10	Not available at this time	April 1, 2021	51	
Information to support sale of a drug to be use the emergency treatment food-producing animal	ed in ent of a	102.20	Not available at this time	April 1, 2021	102	

Fee grouping	Fees for Examination of a Submission — Drugs for Veterinary Use Only				
Fee	Experimental studies certificate				
Fee-setting authority	 <u>Financial Administration Act (FAA)</u>^v <u>Veterinary Drug Evaluation Fees Regulations</u>^{xii} 				
	As at April 1, 2020:				
	 Food and Drugs Act (FDA)^{vii} 				
	 Fees in Respect of Drugs and Medical Devices Order Vill 				
Year fee-setting authority was introduced	1996				
Last year fee-setting authority was amended	2019				
Service standard	60 Days to review application				
Performance result	37 Days to review application				
Application of Low- Materiality Fees Regulations	Not subject to Service Fees Act				

Fee	2019–20 fee amount (\$)	2019–20 total fee revenue (\$)	Fee adjustment date	Adjusted fee amount in 2021–22 (\$)
Information and material to support the issuance of an experimental studies certificate for a drug to be administered to a non-food-producing animal	981.12	Not available at this time	April 1, 2021	979
Information and material to support the issuance of an experimental studies certificate whose protocol is the same as that for a previously authorized experimental studies certificate for a drug to be administered to a non-food-producing animal	490.56	Not available at this time	April 1, 2021	490
Information and material to support the issuance of an experimental studies certificate for a drug to be administered to a foodproducing animal	2,963.80	Not available at this time	April 1, 2021	2,953

Fee	2019–20 fee amount (\$)	2019–20 total fee revenue (\$)	Fee adjustment date	Adjusted fee amount in 2021–22 (\$)
Information and material to support the issuance of an experimental studies certificate whose protocol is the same as that for a previously authorized experimental studies certificate for a drug to be administered to a foodproducing animal	490.56	Not available at this time	April 1, 2021	490

Fee grouping	Fees for Examination of a Submission — Drugs for Veterinary Use Only				
Fee	Notifial	Notifiable change			
Fee-setting authority	 Financial Administration Act (FAA)^v Veterinary Drug Evaluation Fees Regulations^{xii} As at April 1, 2020: Food and Drugs Act (FDA)^{vii} 				
	•	Fees in Respect	of Drugs and M	ledical Devices	O <i>rder</i> ^{viii}
Year fee-setting authority was introduced	1996				
Last year fee-setting authority was amended	2019	2019			
Service standard	90 Day	s to review applic	ation for Notifiat	ole Changes	
Performance result	64 Day	s to review applic	ation for Notifial	ole Changes	
Application of Low- Materiality Fees Regulations	Not sul	Not subject to Service Fees Act			
Fee 2019–20 fee 2019–20 Fee amount (\$) total fee adjustment revenue (\$) date			adjustment date	Adjusted fee amount in 2021–22 (\$)	
Information and material to support an application for Notifiable Change		1,300	Not available at this time	April 1, 2021	2,069

Fee grouping	Fees for Examination of a Submission — Drugs for Veterinary Use Only				rinary Use
Fee	Protoco	ol			
Fee-setting authority	• • As at A	 Financial Administration Act (FAA)^v Veterinary Drug Evaluation Fees Regulations^{xii} As at April 1, 2020: Food and Drugs Act (FDA)^{vii} 			
	•	Fees in Respect	of Drugs and M	<u>ledical Devices (</u>	<u>Order</u> VIII
Year fee-setting authority was introduced	1996				
Last year fee-setting authority was amended	2019				
Service standard		s to review packa ed to 90 Days as			
Performance result	60 Day	s to review packa	ige		
Application of Low- Materiality Fees Regulations	Not sub	bject to <i>Service F</i>	ees Act		
Fee		2019–20 fee amount (\$)	2019–20 total fee revenue (\$)	Fee adjustment date	Adjusted fee amount in 2021–22 (\$)
A protocol that is filed with the Minister and may support a new drug submission, an abbreviated new drug submission, a supplement to a new drug submission or abbreviated new drug submission, a preclinical submission or information and material that is filed for the purpose of obtaining an experimental studies certificate		1,300	Not available at this time	April 1, 2021	2,069

Drug Establishment Licensing Fees

Any person in Canada must obtain a Drug Establishment Licence (DEL) if they are engaged in any of the six regulated activities (fabricate, import, distribute, wholesale, package/label, and test) with respect to human and/or veterinary drugs. A fee is charged for the examination of a DEL application, including all compliance and enforcement and supporting activities needed to ensure that the applicant/licence holder conforms to all regulatory requirements. The DEL fee is calculated on a component basis; therefore, the fee amount varies by application. A DEL fee is charged for the application for a new DEL, an annual licence review of a DEL, certain amendments to a DEL, reinstatement of a suspended DEL, or reactivation of a cancelled or withdrawn DEL.

As of April 1, 2020, a more simplified DEL fee regime was introduced, as indicated in the tables below.

Fee grouping	Drug E	Drug Establishment Licensing Fees				
Fee	Humar	n Drug Establishm	ent Licence Fee	s		
Fee-setting authority	 Financial Administration Act (FAA)^v Fees in Respect of Drugs and Medical Devices Regulations^{vi} 					
Year fee-setting authority was introduced	1998					
Last year fee-setting authority was amended	2011					
Service standard		alendar days to iss				
Performance result	96% of days	f licenses issued (human and vete	rinary) within 25	0 calendar	
Application of Low- Materiality Fees Regulations	Not subject to Service Fees Act					
Fee		2019–20 fee amount (\$)	2019–20 total fee revenue (\$)	Fee adjustment date	Adjusted fee amount in 2021–22 (\$)	
Fabrication - Basic Fee	Э	18,107	Not available	Not	Not	
Fabrication - Each Add Category	litional	4,538	Not available	applicable, fee discontinued	applicable, fee discontinued	
Dosage Form Classes	:			as of April 1,	as of April 1,	
Fabrication - Two class		9,061	Not available	2020	2020	
Fabrication - Three cla	sses	18,107	Not available			
Fabrication - Four clas	ses	22,642	Not available			
Fabrication - Five class	Fabrication - Five classes		Not available			
Fabrication - Six classe	es	31,686	Not available			
Fabrication - Each add		1,819	Not available			

Fee	2019–20 fee amount (\$)	2019–20 total fee	Fee adjustment	Adjusted fee amount in
		revenue (\$)	date	2021–22 (\$)
Fabrication - Sterile dosage forms	9,061	Not available		
Packaging/labelling - Basic Fee	12,107	Not available		
Packaging/labelling - Each Additional Category	3,026	Not available		
Packaging/labelling - Two classes	6,039	Not available		
Packaging/labelling - Three or more classes	9,061	Not available		
Importation/Distribution - Basic Fee	7,551	Not available		
Importation/Distribution - Each Additional Category	1,891	Not available		
Importation/Distribution - Two classes	3,778	Not available		
Importation/Distribution - Three or more classes	7,551	Not available		
Importation/Distribution - Each fabricator	1,819	Not available		
Importation/Distribution - Each additional dosage form class for each fabricator	917	Not available		
Distribution and Wholesaling Fee	4,538	Not available		
Testing - Testing Fee	3,026	Not available		
Drug Analysis Component - Vaccines	30,174	Not available		
Drug Analysis Component - Schedule D Drugs which are not vaccines or whole blood and its components	12,073	Not available		
Drug Analysis Component - Drugs for human use that are prescription drugs, controlled drugs or narcotics	9,061	Not available		
Drug Analysis Component - Drugs for human use, not included in any other item, for which a drug identification number has been assigned	4,538	Not available		

Fee grouping	Drug E	stablishment Li	censing Fees		
Fee	Humar	n Drug Establish	ment Licence Fee	es	
Fee-setting	As at A	April 1, 2020:			
authority	•	Food and Drug	gs Act (FDA) ^{vii}		
	•	Fees in Respe	ect of Drugs and M	ledical Devices	Order ^{viii}
Year fee-setting authority was introduced	2019	2019			
Last year fee-setting authority was amended	Not ap	Not applicable			
Service standard	250 Ca	alendar days to i	issue/ renew licen	se	
Performance result		formance result il 1, 2020	is available, since	the new fees w	ere introduced
Application of Low- Materiality Fees Regulations	Not sul	bject to <i>Service</i>	Fees Act		
Fee		2019–20 fee amount (\$)	2019–20 total fee revenue (\$)	Fee adjustment date	Adjusted fee amount in 2021–22 (\$)
Fabrication - Sterile do form	sage	Not applicable,	Not applicable, as these are	April 1, 2021	41,647
Importation		as these are	new fees as of		28,975
Fabrication - non-steril dosage form	е	new fees as of April 1,	April 1, 2020		28,308
Distribution		2020			13,855
Wholesaling					6,159
Packaging/labelling					6,049
Testing					3,194
Building outside Canad	da				917
(each)		<u> </u>			

Fee grouping	Drug F	etablishment Lice	neina Fees			
Fee	Drug Establishment Licensing Fees Veterinary Drug Establishment Licence Fees					
Fee-setting authority	 Financial Administration Act (FAA)^v Establishment Licensing Fees (Veterinary Drugs) Regulations 					
Year fee-setting authority was introduced	1998					
Last year fee-setting authority was amended	Not applicable					
Service standard		250 Calendar days to issue/ renew license				
Performance result	96% of licenses issued (human and veterinary) within 250 calendar days					
Application of Low- Materiality Fees Regulations	Not su	Not subject to Service Fees Act				
	Fee		2019–20 total fee revenue (\$)	Fee adjustment date	Adjusted fee amount in 2021–22 (\$)	
Fabrication - Basic Fee	9	6,132	Not available	Not applicable,	Not applicable,	
Fabrication - Each Additional Category		1,533	Not available	fee discontinued	fee discontinued	
Dosage Form Classes	Dosage Form Classes:			as of April 1,	as of April 1,	
Fabrication - Two classes		3,066	Not available	2020	2020	
Fabrication - Three classes		6,132	Not available			
Fabrication - Four classes		7,665	Not available			
Fabrication - Five classes		9,198	Not available			
Fabrication - Six classes		10,731	Not available			
Fabrication - Each additional class		613.20	Not available			
Fabrication - Sterile dosage forms		3,066	Not available			
Packaging/labelling - Basic Fee		4,088	Not available			
Packaging/labelling - Each Additional Category		1,022	Not available			
Packaging/labelling - Two classes		2,044	Not available			
Packaging/labelling - Three or more classes		3,066	Not available			
Importation/Distribution - Basic Fee		2,555	Not available			

Fee	2019–20 fee amount (\$)	2019–20 total fee revenue (\$)	Fee adjustment date	Adjusted fee amount in 2021–22 (\$)
Importation/Distribution - Each Additional Category	638.75	Not available		
Importation/Distribution - Two classes	1,277.50	Not available		
Importation/Distribution - Three or more classes	2,555	Not available		
Importation/Distribution - Each fabricator	613.20	Not available		
Importation/Distribution - Each additional dosage form class for each fabricator	306.60	Not available		
Distribution and Wholesaling Fee	1,533	Not available		
Testing - Testing Fee	1,022	Not available		
Drug Analysis Component - Drug Identification Numbers for Veterinary Use	255.50	Not available		

Fee grouping	Drug Establishment Licence Fees					
Fee	Veterinary Drug Establishment Licence Fees					
Fee-setting authority	As at April 1, 2020:					
	Food and Drugs Act (FDA) ^{vii}					
	•	<u>Fees in Respe</u>	ct of Drugs and M	<u>ledical Devices</u>	<u>Order</u> VIII	
Year fee-setting authority was introduced	2019					
Last year fee-setting authority was amended	Not applicable					
Service standard	250 Ca	alendar days to i	ssue/ renew licen	se		
Performance result	No performance result is available, since the new fees were introduced on April 1, 2020					
Application of Low- Materiality Fees Regulations	Not subject to Service Fees Act					
Fee		2019–20 fee amount (\$)	2019–20 total fee revenue (\$)	Fee adjustment date	Adjusted fee amount in 2021–22 (\$)	
Fabrication - Sterile dosage form		Not applicable,	Not applicable, as these are	April 1, 2021	40,407	
Importation		as these are new fees as	new fees as of		13,367	
	Fabrication - non-sterile		April 1, 2020		10,957	
dosage form		of April 1, 2020			0.004	
Distribution		2020			6,031 2,412	
Wholesaling Packaging/labelling					6,049	
Testing					1,641	
Building outside Canada					917	
(each)						

Drug Establishment Licensing Fees - Dealer's Licences

Fees for the examination of an application for a new dealer's licence or the renewal of a dealer's licence; issued under the Narcotic Control Regulations and Part G of the Food and Drug Regulations. There is no fee associated with the application for a new or renewal of a controlled substances licence issued under the Benzodiazepines and Other Targeted Substances Regulations and Part J of the Food and Drug Regulations.

Fee grouping	Drug Establishment Licensing Fees - Dealer's Licences						
Fee	Dealer's Licence Fees - Human Drugs						
	Dealer's Licence Fees - Veterinary Drugs						
Fee-setting	Humai	n Drugs:					
authority	Financial Administration Act (FAA) ^v						
	Fees in Respect of Drugs and Medical Devices Regulations (until						
		March 21 2019	<u>))</u> vi				
	•	Fees in Respe	ct of a Dealer's Li	cences Regulati	ons ^{xiv} (beginning		
		April 1, 2020)					
	Veterir	nary Drugs:					
	•	Financial Adm	inistration Act (FA	<i>A)</i> ^v			
	•	Licensed Deal	ers for Controlled	Drugs and Narc	otics (Veterinary		
		<u>Use) Fees Reg</u>	gulations <u>xv</u>				
Year fee-setting	1998						
authority was							
introduced	.	D 0011					
Last year	Human Drugs: 2011 Veterinary Drugs: Not applicable						
fee-setting authority was	veterir	iary Drugs: Not a	аррисаріе				
amended							
Service standard	270 Ca	270 Calendar days to issue a decision on an application for a new					
			trolled substance				
	applica						
			sue a decision on				
			trolled substance	s, from the recei	pt of a complete		
	application						
Performance result	New: 94% of applications were processed within the service standard						
Application of Law	Renew: 100% of applications were processed within the service standard						
Application of Low- Materiality Fees	Material (>\$151)						
Regulations	Material (>\$151)						
Fee		2019–20 fee	2019-20 total	Fee	Adjusted fee		
		amount (\$)	fee revenue	adjustment	amount in		
			(\$)	date	2021–22 (\$)		
Dealer's Licence Fees	-	5,288	1,121,826	April 1, 2021	5,502		
Human Drugs							
Dealer's Licence Fees -		1,788.50	18,722	April 1, 2021	1,820.62		
Veterinary Drugs							

Medical Device Establishment Licensing Fees

A Medical Device Establishment Licence (MDEL) is required for the activities of importing or selling medical devices for human use in Canada with exceptions^a. A fee is charged for the examination of an MDEL application, including all compliance and enforcement and supporting activities needed to ensure that the applicant/licence holder conforms to all regulatory requirements. The MDEL fee is a flat fee. The same fee is charged for an application for a new MDEL, an annual licence review of an MDEL, and the reinstatement of a suspended MDEL.

Fee grouping	Medical Devices Establishment Licensing Fees					
Fee	Application for new licence and annual review of licence					
Fee-setting authority	 Financial Administration Act (FAA)^v Fees in Respect of Drugs and Medical Devices Regulations^{vi} Beginning April 1, 2020: 					
	•	Food and Drugs Act (FDA) ^{vii} Fees in Respect of Drugs and Medical Devices Order ^{viii}				
Year fee-setting authority was introduced	2000					
Last year fee-setting authority was amended	2019					
Service standard	120 Calendar days to issue/ renew licence					
Performance result	100% of licences issued within 120 calendar days					
Application of Low- Materiality Fees Regulations	Not subject to Service Fees Act					
Fee		2019–20 fee amount (\$)	2019–20 total fee revenue (\$)	Fee adjustment date	Adjusted fee amount in 2021–22 (\$)	
Application for new lice and annual review of li		8,438	9,455,621	April 1, 2021	4,581	

^a As per the Medical Devices Regulations, an MDEL is not required for: a retailer, a health care facility, a manufacturer of Class II, III or IV medical devices who only sells either medical devices for which they hold a valid licence, or medical devices subject to Parts 2 and 3 of the Regulations, a manufacturer of a Class I medical device who imports or distributes solely through a licensed establishment, a person solely selling medical devices subject to Parts 2 and 3 of the Regulations, or a dispenser.

Fees to be Paid for the Examination of an Application in Respect of a Pest Control Product

No person shall manufacture, possess, handle, store, transport, import, distribute or use a pest control product that is not registered under the Pest Control Products Act, except as otherwise authorized under the Act or unless specifically exempted by the Pest Control Products Regulations. Fees for applications to register or to amend the registration of a pest control product are payable by component submitted. The fee payable is the sum of the fees for the submitted components in addition to the basic processing fee.

Fee grouping	Fees to be Paid for the Examination of an Application in Respect of a Pest Control Product					
Fee	Category A Component Based – 655 Days of Review (Conventional Chemicals and Import Maximum Residue Limits)					
Fee-setting authority	Pest Control Products Act xvi Pest Control Products Fees and Charges Regulations xvii					
Year fee-setting authority was introduced	1997					
Last year fee-setting authority was amended	2017					
Service standard	655 Days of Review					
Performance result	100% (5/5 applications met the service standard)					
Application of Low- Materiality Fees Regulations	Material (>\$151): All fees					
Fee	Fee		2019–20 total fee revenue (\$)	Fee adjustment date	Adjusted fee amount in 2021–22 (\$)	
Product Chemistry – active ingredient		5,071	Not available at this time	April 1, 2021	5,277	
Product Chemistry – end-use product or manufacturing concentrate		2,824	Not available at this time	April 1, 2021	2,939	
Toxicology data accompanying an application to register a pest control product that contains a new active ingredient		78,871	Not available at this time	April 1, 2021	82,058	

Fee	2019–20 fee amount (\$)	2019–20 total fee revenue (\$)	Fee adjustment date	Adjusted fee amount in 2021–22 (\$)
Toxicology data accompanying an application to register a pest control product –or to amend a pest control product –that contains an registered active ingredient	16,470	Not available at this time	April 1, 2021	17,136
Toxicology data-acute toxicity studies	3,075	Not available at this time	April 1, 2021	3,200
Exposure data accompanying an application to register a pest control that consists of or that contains a new active ingredient	18,205	Not available at this time	April 1, 2021	18,942
Exposure data accompanying an application to register a pest control product –or to amend the registration of a pest control product –that contains a registered active ingredient, when a new risk assessment is necessary	5,992	Not available at this time	April 1, 2021	6,235
Metabolism data	30,113	Not available at this time	April 1, 2021	31,331
Residue data	16,479	Not available at this time	April 1, 2021	17,146
Environment fate data accompanying an application to register a pest control product that consists of or that contains a new active ingredient	44,410	Not available at this time	April 1, 2021	46,205
Environmental fate data accompanying an application to register a pest control product ,or to amend the registration of a pest control product, that contains a registered active ingredient , when a new risk assessment is necessary	24,593	Not available at this time	April 1, 2021	25,587

Fee	2019–20 fee amount (\$)	2019–20 total fee revenue (\$)	Fee adjustment date	Adjusted fee amount in 2021–22 (\$)
Environment toxicology data accompanying an application to register a pest control product that consists of or that contains a new active ingredient	38,784	Not available at this time	April 1, 2021	40,352
Environmental toxicology data accompanying an application to register a pest control product, or to amend the registration of a pest control product, that contains a registered active ingredient, when a new risk assessment is necessary	24,648	Not available at this time	April 1, 2021	25,644
Value and effectiveness data for a pest control product	944	Not available at this time	April 1, 2021	983
Specification of maximum residue limit for a previously unexamined pest control product	130,531	Not available at this time	April 1, 2021	135,805
Specification of maximum residue limit for an unregistered use of a previously examined pest control product	16,479	Not available at this time	April 1, 2021	17,146
Processing	1,180	Not available at this time	April 1, 2021	1,229

Fee grouping	Fees to be Paid for the Examination of an Application in Respect of a Pest Control Product		
Fee	Category A Component Based – 555 Days (Reduced risk, other biopesticides, non-conventionals, non-straight-chain lepidopteran pheromone)		
Fee-setting authority	 <u>Pest Control Products Act</u> xvi <u>Pest Control Products Fees and Charges Regulations</u> xvii 		
Year fee-setting authority was introduced	1997		
Last year fee-setting authority was amended	2017		
Service standard	555 Days of Review		
Performance result	82% (14/17 applications met the service standard)		
Application of Low- Materiality Fees Regulations	Material (>\$151): All fees		

Fee	2019–20 fee amount (\$)	2019–20 total fee revenue (\$)	Fee adjustment date	Adjusted fee amount in 2021–22 (\$)
Product Chemistry – active ingredient	5,071	Not available at this time	April 1, 2021	5,277
Product Chemistry – end-use product or manufacturing concentrate	2,824	Not available at this time	April 1, 2021	2,939
Toxicology data accompanying an application to register a pest control product that contains a new active ingredient	78,871	Not available at this time	April 1, 2021	82,058
Toxicology data accompanying an application to register a pest control product –or to amend a pest control product –that contains an registered active ingredient	16,470	Not available at this time	April 1, 2021	17,136
Toxicology data-acute toxicity studies	3,075	Not available at this time	April 1, 2021	3,200
Exposure data accompanying an application to register a pest control that consists of or that contains a new active ingredient	18,205	Not available at this time	April 1, 2021	18,942

Fee	2019–20 fee amount (\$)	2019–20 total fee revenue (\$)	Fee adjustment date	Adjusted fee amount in 2021–22 (\$)
Exposure data accompanying an application to register a pest control product –or to amend the registration of a pest control product –that contains a registered active ingredient, when a new risk assessment is necessary	5,992	Not available at this time	April 1, 2021	6,235
Metabolism data	30,113	Not available at this time	April 1, 2021	31,331
Residue data	16,479	Not available at this time	April 1, 2021	17,146
Environment fate data accompanying an application to register a pest control product that consists of or that contains a new active ingredient	44,410	Not available at this time	April 1, 2021	46,205
Environmental fate data accompanying an application to register a pest control product ,or to amend the registration of a pest control product, that contains a registered active ingredient , when a new risk assessment is necessary	24,593	Not available at this time	April 1, 2021	25,587
Environment toxicology data accompanying an application to register a pest control product that consists of or that contains a new active ingredient	38,784	Not available at this time	April 1, 2021	40,352
Environmental toxicology data accompanying an application to register a pest control product ,or to amend the registration of a pest control product, that contains a registered active ingredient , when a new risk assessment is necessary	24,648	Not available at this time	April 1, 2021	25,644
Value and effectiveness data for a pest control product	944	Not available at this time	April 1, 2021	983
Registration of a new active ingredient – food use	7,529	Not available at this time	April 1, 2021	7,834

Fee	2019–20 fee amount (\$)	2019–20 total fee revenue (\$)	Fee adjustment date	Adjusted fee amount in 2021–22 (\$)
Registration of a new active ingredient – non-food use	4,517	Not available at this time	April 1, 2021	4,701
Amendment of registration – new risk assessment necessary-environmental fate data, environmental toxicity data or exposure data	3,012	Not available at this time	April 1, 2021	3,135
Processing	1,180	Not available at this time	April 1, 2021	1,229

Fee grouping	Fees to be Paid for the Examination of an Application in Respect of a Pest Control Product
Fee	Category A Component Based – 470 Days of Review (Microbials including User Requested Minor Use Registration (URMUR), and URMUR for conventional chemical, reduced risk, other biopesticides, non-conventionals, non-straight-chain lepidopteran pheromone)
Fee-setting authority	 <u>Pest Control Products Act</u> xvi <u>Pest Control Products Fees and Charges Regulations xvii</u>
Year fee-setting authority was introduced	1997
Last year fee-setting authority was amended	2017
Service standard	470 Days of Review
Performance result	N/A (0 applications completed in 2019-20)
Application of Low- Materiality Fees Regulations	Material (>\$151): All fees

Regulations				
Fee	2019–20 fee amount (\$)	2019–20 total fee revenue (\$)	Fee adjustment date	Adjusted fee amount in 2021–22 (\$)
Product Chemistry – active ingredient	5,071	Not available at this time	April 1, 2021	5,277
Product Chemistry – end-use product or manufacturing concentrate	2,824	Not available at this time	April 1, 2021	2,939
Toxicology data accompanying an application to register a pest control product that contains a new active ingredient	78,871	Not available at this time	April 1, 2021	82,058
Toxicology data accompanying an application to register a pest control product –or to amend a pest control product –that contains an registered active ingredient	16,470	Not available at this time	April 1, 2021	17,136
Toxicology data-acute toxicity studies	3,075	Not available at this time	April 1, 2021	3,200
Exposure data accompanying an application to register a pest control that consists of or that contains a new active ingredient	18,205	Not available at this time	April 1, 2021	18,942

Fee	2019–20 fee amount (\$)	2019–20 total fee revenue (\$)	Fee adjustment date	Adjusted fee amount in 2021–22 (\$)
Exposure data accompanying an application to register a pest control product –or to amend the registration of a pest control product –that contains a registered active ingredient, when a new risk assessment is necessary	5,992	Not available at this time	April 1, 2021	6,235
Metabolism data	30,113	Not available at this time	April 1, 2021	31,331
Residue data	16,479	Not available at this time	April 1, 2021	17,146
Environment fate data accompanying an application to register a pest control product that consists of or that contains a new active ingredient	44,410	Not available at this time	April 1, 2021	46,205
Environmental fate data accompanying an application to register a pest control product ,or to amend the registration of a pest control product, that contains a registered active ingredient , when a new risk assessment is necessary	24,593	Not available at this time	April 1, 2021	25,587
Environment toxicology data accompanying an application to register a pest control product that consists of or that contains a new active ingredient	38,784	Not available at this time	April 1, 2021	40,352
Environmental toxicology data accompanying an application to register a pest control product ,or to amend the registration of a pest control product, that contains a registered active ingredient , when a new risk assessment is necessary	24,648	Not available at this time	April 1, 2021	25,644
Value and effectiveness data for a pest control product	944	Not available at this time	April 1, 2021	983
Registration of a new active ingredient – food use	7,529	Not available at this time	April 1, 2021	7,834

Fee	2019–20 fee amount (\$)	2019–20 total fee revenue (\$)	Fee adjustment date	Adjusted fee amount in 2021–22 (\$)
Registration of a new active ingredient – non-food use	4,517	Not available at this time	April 1, 2021	4,701
Amendment of registration – new risk assessment necessary-environmental fate data, environmental toxicity data or exposure data	3,012	Not available at this time	April 1, 2021	3,135
Processing	1,180	Not available at this time	April 1, 2021	1,229

Fee grouping		Fees to be Paid for the Examination of an Application in Respect of a Pest Control Product			
Fee		ory A Component oteran pheromone ration)			
Fee-setting authority	•	Pest Control Pro		Charges Regula	a <u>tions</u> xvii
Year fee-setting authority was introduced	1997	1997			
Last year fee-setting authority was amended	2017	2017			
Service standard	285 Days of Review				
Performance result	N/A (0	N/A (0 applications completed in 2019-20)			
Application of Low- Materiality Fees Regulations	Material (>\$151): All fees				
Fee		2019–20 fee amount (\$)	2019–20 total fee revenue (\$)	Fee adjustment date	Adjusted fee amount in 2021–22 (\$)
Registration of new active ingredient		603	Not available at this time	April 1, 2021	629
Amendment of registra	ition	302	Not available at this time	April 1, 2021	316

Fee grouping	Fees to be Paid for the Examination of an Application in Respect of a Pest Control Product
Fee	Category A Component Based – Submissions with atypical timelines and joint reviews
Fee-setting authority	 Pest Control Products Act xvi Pest Control Products Fees and Charges Regulations xvii
Year fee-setting authority was introduced	1997
Last year fee-setting authority was amended	2017
Service standard	Variable as per <u>Management of Submission Policy</u> ^{xviii} Appendix I, Table 1
Performance result	73% (8/11 applications met the service standard)
Application of Low- Materiality Fees Regulations	Material (>\$151): All fees

Fee	2019–20 fee amount (\$)	2019–20 total fee revenue (\$)	Fee adjustment date	Adjusted fee amount in 2021–22 (\$)
Product Chemistry – active ingredient	5,071	Not available at this time	April 1, 2021	5,277
Product Chemistry – end-use product or manufacturing concentrate	2,824	Not available at this time	April 1, 2021	2,939
Toxicology data accompanying an application to register a pest control product that contains a new active ingredient	78,871	Not available at this time	April 1, 2021	82,058
Toxicology data accompanying an application to register a pest control product –or to amend a pest control product –that contains an registered active ingredient	16,470	Not available at this time	April 1, 2021	17,136
Toxicology data-acute toxicity studies	3,075	Not available at this time	April 1, 2021	3,200
Exposure data accompanying an application to register a pest control that consists of or that contains a new active ingredient	18,205	Not available at this time	April 1, 2021	18,942

Fee	2019–20 fee amount (\$)	2019–20 total fee revenue (\$)	Fee adjustment date	Adjusted fee amount in 2021–22 (\$)
Exposure data accompanying an application to register a pest control product –or to amend the registration of a pest control product –that contains a registered active ingredient, when a new risk assessment is necessary	5,992	Not available at this time	April 1, 2021	6,235
Metabolism data	30,113	Not available at this time	April 1, 2021	31,331
Residue data	16,479	Not available at this time	April 1, 2021	17,146
Environment fate data accompanying an application to register a pest control product that consists of or that contains a new active ingredient	44,410	Not available at this time	April 1, 2021	46,205
Environmental fate data accompanying an application to register a pest control product, or to amend the registration of a pest control product, that contains a registered active ingredient, when a new risk assessment is necessary	24,593	Not available at this time	April 1, 2021	25,587
Environment toxicology data accompanying an application to register a pest control product that consists of or that contains a new active ingredient	38,784	Not available at this time	April 1, 2021	40,352
Environmental toxicology data accompanying an application to register a pest control product, or to amend the registration of a pest control product, that contains a registered active ingredient, when a new risk assessment is necessary	24,648	Not available at this time	April 1, 2021	25,644
Value and effectiveness data for a pest control product	944	Not available at this time	April 1, 2021	983
Registration of a new active ingredient – food use	7,529	Not available at this time	April 1, 2021	7,834

Fee	2019–20 fee amount (\$)	2019–20 total fee revenue (\$)	Fee adjustment date	Adjusted fee amount in 2021–22 (\$)
Registration of a new active ingredient – non-food use	4,517	Not available at this time	April 1, 2021	4,701
Amendment of registration – new risk assessment necessary-environmental fate data, environmental toxicity data or exposure data	3,012	Not available at this time	April 1, 2021	3,135
Registration of new active ingredient	603	Not available at this time	April 1, 2021	629
Amendment of registration	302	Not available at this time	April 1, 2021	316
Specification of maximum residue limit for a previously unexamined pest control product	130,531	Not available at this time	April 1, 2021	135,805
Specification of maximum residue limit for an unregistered use of a previously examined pest control product	16,479	Not available at this time	April 1, 2021	17,146
Processing	1,180	Not available at this time	April 1, 2021	1,229

Fee grouping		Fees to be Paid for the Examination of an Application in Respect of a Pest Control Product				
Fee	Chemi	Category B Component Based – 425 Days of Review (Conventional Chemicals including emergency use and New Import Maximum Residue Limits for previously assessed active ingredient)				
Fee-setting authority	•	Pest Control Pro		l Charges Regul	ations xvii	
Year fee-setting authority was introduced	1997					
Last year fee-setting authority was amended	2017					
Service standard	425 Da	ays of Review				
Performance result	86% (2	201/233 applicatio	ns met the servi	ce standard)		
Application of Low- Materiality Fees Regulations	Materia	Material (>\$151): All fees				
Fee		2019–20 fee amount (\$)	2019–20 total fee revenue (\$)	Fee adjustment date	Adjusted fee amount in 2021–22 (\$)	
Product Chemistry – a ingredient		5,071	Not available at this time	April 1, 2021	5,277	
Product Chemistry – e product or manufacturi concentrate		2,824	Not available at this time	April 1, 2021	2,939	
Toxicology data accompanying an appl to register a pest contr product –or to amend a control product –that contains an registered ingredient	gy data anying an application er a pest control —or to amend a pest product –that an registered active				17,136	
Toxicology data-acute toxicity studies		3,075	Not available at this time	April 1, 2021	3,200	
Exposure data - other		5,426	Not available at this time	April 1, 2021	5,646	
Metabolism data		30,113	Not available at this time	April 1, 2021	31,331	
Residue data		16,479	Not available at this time	April 1, 2021	17,146	
Environmental fate dat other	a -	12,013	Not available at this time	April 1, 2021	12,500	

Fee	2019–20 fee amount (\$)	2019–20 total fee revenue (\$)	Fee adjustment date	Adjusted fee amount in 2021–22 (\$)
Environmental toxicology data - other	2,566	Not available at this time	April 1, 2021	2,671
Value and effectiveness data for a pest control product	944	Not available at this time	April 1, 2021	983
Specification of maximum residue limit for an unregistered use of a previously examined pest control product	16,479	Not available at this time	April 1, 2021	17,146
Processing	1,180	Not available at this time	April 1, 2021	1,229

Fee grouping	Fees to be Paid for the Examination of an Application in Respect of a Pest Control Product			
Fee	Category B Component Based – 360 Days of Review (Reduced risk, other biopesticides, non-conventionals, non-straight chain lepidopteran pheromone including emergency use)			
Fee-setting authority	 Pest Control Products Act xvi Pest Control Products Fees and Charges Regulations xvii 			
Year fee-setting authority was introduced	1997			
Last year fee-setting authority was amended	2017			
Service standard	360 Days of Review			
Performance result	100% (5/5 applications met the service standard)			
Application of Low- Materiality Fees Regulations	Material (>\$151): All fees			

Fee	2019–20 fee amount (\$)	2019–20 total fee revenue (\$)	Fee adjustment date	Adjusted fee amount in 2021–22 (\$)
Product Chemistry – active ingredient	5,071	Not available at this time	April 1, 2021	5,277
Product Chemistry – end-use product or manufacturing concentrate	2,824	Not available at this time	April 1, 2021	2,939
Toxicology data accompanying an application to register a pest control product –or to amend a pest control product –that contains an registered active ingredient	16,470	Not available at this time	April 1, 2021	17,136
Toxicology data-acute toxicity studies	3,075	Not available at this time	April 1, 2021	3,200
Exposure data - other	5,426	Not available at this time	April 1, 2021	5,646
Metabolism data	30,113	Not available at this time	April 1, 2021	31,331
Residue data	16,479	Not available at this time	April 1, 2021	17,146
Environmental fate data - other	12,013	Not available at this time	April 1, 2021	12,500
Environmental toxicology data - other	2,566	Not available at this time	April 1, 2021	2,671

Fee	2019–20 fee amount (\$)	2019–20 total fee revenue (\$)	Fee adjustment date	Adjusted fee amount in 2021–22 (\$)
Value and effectiveness data for a pest control product	944	Not available at this time	April 1, 2021	983
Amendment of registration – data required, label changes	1,506	Not available at this time	April 1, 2021	1,568
Amendment of registration – data required, other	1,206	Not available at this time	April 1, 2021	1,256
Processing	1,180	Not available at this time	April 1, 2021	1,229

Fee grouping		Fees to be Paid for the Examination of an Application in Respect of a Pest Control Product			
Fee		ory B Component t chain lepidoptera			
Fee-setting authority	•	Pest Control Products Act xvi Pest Control Products Fees and Charges Regulations xvii			
Year fee-setting authority was introduced	1997	1997			
Last year fee-setting authority was amended	2017				
Service standard	240 Da	ys of Review			
Performance result	89% (1	6/18 applications	met the service	standard)	
Application of Low- Materiality Fees Regulations		al (>\$151): All fee		,	
Fee	2019–20 fee 2019–20 Fee Adjusted amount (\$) total fee adjustment amount in revenue (\$) date 2021–22 (
Amendment of registra data required, label cha		1,506	Not available at this time	April 1, 2021	1,568
Amendment of registra data required, other	endment of registration – 1,206		Not available at this time	April 1, 2021	1,256
Amendment of registra	tion	302	Not available at this time	April 1, 2021	316

Fee grouping		Fees to be Paid for the Examination of an Application in Respect of a Pest Control Product			
Fee		ory B Component ation rate changes)			
Fee-setting authority	• •	Pest Control Pro		Charges Regul	ations_xvii
Year fee-setting authority was introduced	1997	1997			
Last year fee-setting authority was amended	2017				
Service standard	158 Da	ays of Review			
Performance result	88% (3	35/40 applications	met the service	standard)	
Application of Low- Materiality Fees Regulations	Materia	al (>\$151): All fee	s		
Fee		2019–20 fee amount (\$)	2019–20 total fee revenue (\$)	Fee adjustment date	Adjusted fee amount in 2021–22 (\$)
Value and effectivenes for a pest control produ		944	Not available at this time	April 1, 2021	983
Amendment of registra data required, label cha	ation – 1,506 Not availab			April 1, 2021	1,568
Amendment of registra no data required, other		302	Not available at this time	April 1, 2021	316
Processing		1,180	Not available at this time	April 1, 2021	1,229

Fee grouping	Fees to be Paid for the Examination of an Application in Respect of a Pest Control Product
Fee	Category B Component Based – Submissions with atypical timelines and joint reviews
Fee-setting authority	 <u>Pest Control Products Act</u> xvi <u>Pest Control Products Fees and Charges Regulations</u> xvii
Year fee-setting authority was introduced	1997
Last year fee-setting authority was amended	2017
Service standard	Variable as per <u>Management of Submission Policy</u> ^{xviii} Appendix I, Table 2
Performance result	N/A (0 applications completed in 2019-20)
Application of Low- Materiality Fees Regulations	Material (>\$151): All fees

Fee	2019–20 fee amount (\$)	2019–20 total fee revenue (\$)	Fee adjustment date	Adjusted fee amount in 2021–22 (\$)
Product Chemistry – active ingredient	5,071	Not available at this time	April 1, 2021	5,277
Product Chemistry – end-use product or manufacturing concentrate	2,824	Not available at this time	April 1, 2021	2,939
Toxicology data accompanying an application to register a pest control product –or to amend a pest control product –that contains an registered active ingredient	16,470	Not available at this time	April 1, 2021	17,136
Toxicology data-acute toxicity studies	3,075	Not available at this time	April 1, 2021	3,200
Exposure data-other	5,426	Not available at this time	April 1, 2021	5,646
Metabolism data	30,113	Not available at this time	April 1, 2021	31,331
Residue data	16,479	Not available at this time	April 1, 2021	17,146
Environmental fate data - other	12,013	Not available at this time	April 1, 2021	12,500
Environmental toxicology data - other	2,566	Not available at this time	April 1, 2021	2,671

Fee	2019–20 fee amount (\$)	2019–20 total fee revenue (\$)	Fee adjustment date	Adjusted fee amount in 2021–22 (\$)
Value and effectiveness data for a pest control product	944	Not available at this time	April 1, 2021	983
Amendment of registration - data required, label changes	1,506	Not available at this time	April 1, 2021	1,568
Amendment of registration - data required, other	1,206	Not available at this time	April 1, 2021	1,256
Amendment of registration - no data required	302	Not available at this time	April 1, 2021	316
Amendment of registration	302	Not available at this time	April 1, 2021	316
Specification of maximum residue limit for an unregistered use of a previously examined pest control product	16,479	Not available at this time	April 1, 2021	17,146
Processing	1,180	Not available at this time	April 1, 2021	1,229

Fee grouping		Fees to be Paid for the Examination of an Application in Respect of a Pest Control Product				
Fee		ory C Component duct Labels, Additi				
Fee-setting authority	•	 <u>Pest Control Products Act</u> xvi <u>Pest Control Products Fees and Charges Regulations xvii</u> 				
Year fee-setting authority was introduced	1997	1997				
Last year fee-setting authority was amended	2017	2017				
Service standard	240 Da	240 Days of Review				
Performance result	97% (6	880/701 applicatio	ns met the servi	ce standard)		
Application of Low- Materiality Fees Regulations	_	al (>\$151): All fee		,		
Fee		2019–20 fee amount (\$)	2019–20 total fee revenue (\$)	Fee adjustment date	Adjusted fee amount in 2021–22 (\$)	
Amendment of registra no data required	ition –	302	Not available at this time	April 1, 2021	316	
Amendment of registra	ition	302	Not available at this time	April 1, 2021	316	
Processing		1,180	Not available at this time	April 1, 2021	1,229	

Fee grouping	Pest C	Fees to be Paid for the Examination of an Application in Respect of a Pest Control Product			
Fee	to TGA	ory C Component AI, ISP, MA or EP strative Re-instate	Product Chemis		
Fee-setting authority	•	 Pest Control Products Act xvi Pest Control Products Fees and Charges Regulations xvii 			
Year fee-setting authority was introduced	1997	1997			
Last year fee-setting authority was amended	2017	2017			
Service standard	180 Da	ays of Review			
Performance result	99% (1	22/123 applicatio	ns met the servi	ce standard)	
Application of Low- Materiality Fees Regulations	Materia	al (>\$151): All fee	S		
Fee		2019–20 fee amount (\$)	2019–20 total fee revenue (\$)	Fee adjustment date	Adjusted fee amount in 2021–22 (\$)
Amendment of registra no data required	ition –	302	Not available at this time	April 1, 2021	316
Amendment of registra	ition	302	Not available at this time	April 1, 2021	316
Processing		1,180	Not available at this time	April 1, 2021	1,229

Fee grouping		Fees to be Paid for the Examination of an Application in Respect of a Pest Control Product				
Fee		ory C Component nt reviews	Based – Submis	ssions with atypi	cal timelines	
Fee-setting authority	•	 <u>Pest Control Products Act</u> xvi <u>Pest Control Products Fees and Charges Regulations</u> xvii 				
Year fee-setting authority was introduced	1997	1997				
Last year fee-setting authority was amended	2017	2017				
Service standard	Variable 3	e as per <mark>Manage</mark> 3	ment of Submiss	sion Policy ^{xviii} , A _l	opendix I,	
Performance result	0% (0/	1 applications me	t the service star	ndard)		
Application of Low- Materiality Fees Regulations		al (>\$151): All fee	5	,		
Fee		2019–20 fee amount (\$)	2019–20 total fee revenue (\$)	Fee adjustment date	Adjusted fee amount in 2021–22 (\$)	
Amendment of registra no data required	tion –	302	Not available at this time	April 1, 2021	316	
Amendment of registration		302	Not available at this time	April 1, 2021	316	
Processing		1,180	Not available at this time	April 1, 2021	1,229	

Fee grouping	Fees to be Paid for the Examination of an Application in Respect of a Pest Control Product					
Fee	_	Category D Component Based – 247 Days of Review (Registration Renewal)				
Fee-setting authority	• •	 Pest Control Products Act xvi Pest Control Products Fees and Charges Regulations xvii 				
Year fee-setting authority was introduced	1997	1997				
Last year fee-setting authority was amended	2017	2017				
Service standard	247 Da	ys of Review				
Performance result	100% (970/970 applicati	ons met the serv	vice standard)		
Application of Low- Materiality Fees Regulations	Low-m	Low-materiality (\$51–\$151): All fees				
Fee	2019–20 fee amount (\$)	2019–20 total fee revenue (\$)	Fee adjustment date	Adjusted fee amount in 2021–22 (\$)		
Renewal		84	Not available at this time	April 1, 2021	88	

Fee grouping		Fees to be Paid for the Examination of an Application in Respect of a Pest Control Product			
Fee	(Regist	ory D Component tration/Amendmer n pest control prod	nt to Registration	of active ingred	
Fee-setting authority	•	Pest Control Pro		Charges Regula	ations_xvii
Year fee-setting authority was introduced	1997				
Last year fee-setting authority was amended	2017				
Service standard	46 Day	s of Review			
Performance result	33% (1	/3 applications m	et the service sta	andard)	
Application of Low- Materiality Fees Regulations		al (>\$151): All fee		,	
Fee		2019–20 fee amount (\$)	2019–20 total fee revenue (\$)	Fee adjustment date	Adjusted fee amount in 2021–22 (\$)
Registration of active ingredient to be used in pest control product manufactured only for export		8,144	Not available at this time	April 1, 2021	8,474
Amendment to Registration of active ingredient to be used in pest control product manufactured only for export		1,180	Not available at this time	April 1, 2021	1,229

Fee grouping	Fees to be Paid for the Examination of an Application in Respect of a Pest Control Product						
Fee	Catego	ry D Component	Based – 42 Day	s of Review (Ma	ster Copies)		
Fee-setting authority	•	 <u>Pest Control Products Act</u> xvi <u>Pest Control Products Fees and Charges Regulations</u> xvii 					
Year fee-setting authority was introduced	1997	1997					
Last year fee-setting authority was amended	2017	2017					
Service standard	42 Day	s of Review					
Performance result	100% (61/61 applications	s met the service	e standard)			
Application of Low- Materiality Fees Regulations	Materia	Material (>\$151): All fees					
Fee		2019–20 fee amount (\$)	2019–20 total fee revenue (\$)	Fee adjustment date	Adjusted fee amount in 2021–22 (\$)		
Processing		1,180	Not available at this time	April 1, 2021	1,229		

Fee grouping	Fees to be Paid for the Examination of an Application in Respect of a Pest Control Product				
Fee	Catego	ory D Component	Based – 10 Day	s of Review (Pri	vate Labels)
Fee-setting authority	• •	 Pest Control Products Act xvi Pest Control Products Fees and Charges Regulations xvii 			
Year fee-setting authority was introduced	1997	1997			
Last year fee-setting authority was amended	2017				
Service standard	10 Day	s of Review			
Performance result	100% (5/5 applications n	net the service s	tandard)	
Application of Low- Materiality Fees Regulations	Materia	Material (>\$151): All fees			
Fee		2019–20 fee amount (\$)	2019–20 total fee revenue (\$)	Fee adjustment date	Adjusted fee amount in 2021–22 (\$)
Processing		1,180	Not available at this time	April 1, 2021	1,229

Fee grouping	Fees to be Paid for the Examination of an Application in Respect of a Pest Control Product
Fee	Category E Component Based – 159 Days of Review (Research Authorizations for New Technical Grade Active Ingredients)
Fee-setting authority	 <u>Pest Control Products Act</u> xvi <u>Pest Control Products Fees and Charges Regulations</u> xvii
Year fee-setting authority was introduced	1997
Last year fee-setting authority was amended	2017
Service standard	159 Days of Review
Performance result	69% (20/29 applications met the service standard)
Application of Low- Materiality Fees Regulations	Material (>\$151): All fees

rtogalationo				
Fee	2019–20 fee amount (\$)	2019–20 total fee revenue (\$)	Fee adjustment date	Adjusted fee amount in 2021–22 (\$)
Research authorization – major crops, other than research authorizations set out in paragraphs (c) and (d)	5,286	Not available at this time	April 1, 2021	5,500
Research authorization – minor use crops, other than research authorizations set out in paragraphs (c) and (d)	5,286	Not available at this time	April 1, 2021	5,500
Research authorization – microbial agents, semiochemicals and any substance listed in subparagraph 1(d) (ii) of these regulations	1,267	Not available at this time	April 1, 2021	1,319
Research authorization – greenhouse crops and non-agricultural uses	1,267	Not available at this time	April 1, 2021	1,319

Fee grouping		Fees to be Paid for the Examination of an Application in Respect of a Pest Control Product					
Fee		ory E Component izations for New U					
Fee-setting authority	•	 Pest Control Products Act xvi Pest Control Products Fees and Charges Regulations xvii 					
Year fee-setting authority was introduced	1997	1997					
Last year fee-setting authority was amended	2017	2017					
Service standard	69 Day	69 Days of Review					
Performance result	79% (3	7/47 applications	met the service	standard)			
Application of Low- Materiality Fees Regulations	Materia	Material (>\$151): All fees					
Fee		2019–20 fee amount (\$)	2019–20 total fee revenue (\$)	Fee adjustment date	Adjusted fee amount in 2021–22 (\$)		
Research authorization – major crops, other than research authorizations set out in paragraphs (c) and (d)		5,286	Not available at this time	April 1, 2021	5,500		
Research authorization		5,286	Not available	April 1, 2021	5,500		

at this time

Not available

Not available

at this time

at this time

April 1, 2021

April 1, 2021

1,319

1,319

1,267

1,267

minor use crops, other than

research authorizations set out in paragraphs (c) and (d) Research authorization –

semiochemicals and any substance listed in subparagraph 1(d) (ii) of these regulations

Research authorization -

greenhouse crops and non-

microbial agents,

agricultural uses

Fee grouping		Fees to be Paid for the Examination of an Application in Respect of a Pest Control Product				
Fee		ory E Component lation for Research			search	
Fee-setting authority	•	Pest Control Products Act xvi Pest Control Products Fees and Charges Regulations xvii				
Year fee-setting authority was introduced	1997	1997				
Last year fee-setting authority was amended	2017					
Service standard	30 Day	s of Review				
Performance result	93% (2	7/29 applications	met the service	standard)		
Application of Low- Materiality Fees Regulations	Materia	Material (>\$151): All fees				
Fee		2019–20 fee amount (\$)	2019–20 total fee revenue (\$)	Fee adjustment date	Adjusted fee amount in 2021–22 (\$)	
Research notifications		258	Not available at this time	April 1, 2021	270	

Fee grouping	Fees to be Paid for the Examination of an Application in Respect of a Pest Control Product				
Fee	Category F Component Based – 45 Days of Review (Registration and amendments to registered pest control products via notification)				
Fee-setting authority	 <u>Pest Control Products Act</u> xvi <u>Pest Control Products Fees and Charges Regulations</u> xvii 				
Year fee-setting authority was introduced	1997				
Last year fee-setting authority was amended	2017				
Service standard	45 Days of Review				
Performance result	98% (926/945 applications met the service standard)				
Application of Low- Materiality Fees Regulations	Material (>\$151): All fees				
Fee		2019–20 fee amount (\$)	2019–20 total fee revenue (\$)	Fee adjustment date	Adjusted fee amount in 2021–22 (\$)
Applications not mentioned in schedules		258	Not available at this time	April 1, 2021	270

Fee grouping	Fees to be Paid for the Examination of an Application in Respect of a Pest Control Product
Fee	Category L Component Based – 425 Days of Review (Equivalency and data compensation assessment of end-use product and manufacturing concentrate with partial data package - conventional chemical)
Fee-setting authority	 <u>Pest Control Products Act</u> xvi <u>Pest Control Products Fees and Charges Regulations</u> xvii
Year fee-setting authority was introduced	1997
Last year fee-setting authority was amended	2017
Service standard	425 Days of Review
Performance result	76% (34/45 applications met the service standard)
Application of Low- Materiality Fees Regulations	Material (>\$151): All fees

Fee	2019–20 fee amount (\$)	2019–20 total fee revenue (\$)	Fee adjustment date	Adjusted fee amount in 2021–22 (\$)
Product Chemistry – active ingredient	5,071	Not available at this time	April 1, 2021	5,277
Product Chemistry – end-use product or manufacturing concentrate	2,824	Not available at this time	April 1, 2021	2,939
Toxicology data accompanying an application to register a pest control product –or to amend a pest control product –that contains an registered active ingredient	16,470	Not available at this time	April 1, 2021	17,136
Toxicology data-acute toxicity studies	3,075	Not available at this time	April 1, 2021	3,200
Exposure data - other	5,426	Not available at this time	April 1, 2021	5,646
Metabolism data	30,113	Not available at this time	April 1, 2021	31,331
Residue data	16,479	Not available at this time	April 1, 2021	17,146
Environmental fate data - other	12,013	Not available at this time	April 1, 2021	12,500
Environmental toxicology data – other	2,566	Not available at this time	April 1, 2021	2,671

Fee	2019–20 fee amount (\$)	2019–20 total fee revenue (\$)	Fee adjustment date	Adjusted fee amount in 2021–22 (\$)
Value and effectiveness data for a pest control product	944	Not available at this time	April 1, 2021	983
Identification of compensable data	2,251	Not available at this time	April 1, 2021	2,343
Processing	1,180	Not available at this time	April 1, 2021	1,229

Fee grouping	Fees to be Paid for the Examination of an Application in Respect of a Pest Control Product				
Fee	Category L Component Based – 365 Days of Review (Equivalency and data compensation assessment of active ingredient, end-use product and manufacturing concentrate with no data)				
Fee-setting authority	 <u>Pest Control Products Act</u> xvi <u>Pest Control Products Fees and Charges Regulations</u> xvii 				
Year fee-setting authority was introduced	1997				
Last year fee-setting authority was amended	2017				
Service standard	365 Days of Review				
Performance result	90% (7	6/84 applications	met the service	standard)	
Application of Low- Materiality Fees Regulations	Material (>\$151): All fees				
Fee		2019–20 fee amount (\$)	2019–20 total fee revenue (\$)	Fee adjustment date	Adjusted fee amount in 2021–22 (\$)
Product Chemistry – active ingredient		5,071	Not available at this time	April 1, 2021	5,277
Product Chemistry – end-use product or manufacturing concentrate		2,824	Not available at this time	April 1, 2021	2,939
Identification of compensable data		2,251	Not available at this time	April 1, 2021	2,343
Processing		1,180	Not available at this time	April 1, 2021	1,229

Fee grouping	Fees to be Paid for the Examination of an Application in Respect of a Pest Control Product
Fee	Category L Component Based — 360 Days of Review (Equivalency and data compensation assessment of end-use product and manufacturing concentrate with partial data package - reduced risk, other biopesticides, non-conventionals, non-straight chain lepidopteran pheromone)
Fee-setting	Pest Control Products Act xvi
authority	
	Pest Control Products Fees and Charges Regulations xvii
Year fee-setting	1997
authority was	
introduced	
Last year	2017
fee-setting	
authority was	
amended	
Service standard	360 Days of Review
Performance result	100% (1/1 applications met the service standard)
Application of Low-	Material (>\$151): All fees
Materiality Fees	
Regulations	

Fee	2019–20 fee amount (\$)	2019–20 total fee revenue (\$)	Fee adjustment date	Adjusted fee amount in 2021–22 (\$)
Product Chemistry – active ingredient	5,071	Not available at this time	April 1, 2021	5,277
Product Chemistry – end-use product or manufacturing concentrate	2,824	Not available at this time	April 1, 2021	2,939
Toxicology data accompanying an application to register a pest control product –or to amend a pest control product –that contains an registered active ingredient	16,470	Not available at this time	April 1, 2021	17,136
Toxicology data-acute toxicity studies	3,075	Not available at this time	April 1, 2021	3,200
Exposure data - other	5,426	Not available at this time	April 1, 2021	5,646
Metabolism data	30,113	Not available at this time	April 1, 2021	31,331
Residue data	16,479	Not available at this time	April 1, 2021	17,146
Environmental fate data - other	12,013	Not available at this time	April 1, 2021	12,500

Fee	2019–20 fee amount (\$)	2019–20 total fee revenue (\$)	Fee adjustment date	Adjusted fee amount in 2021–22 (\$)
Environmental toxicology data – other	2,566	Not available at this time	April 1, 2021	2,671
Value and effectiveness data for a pest control product	944	Not available at this time	April 1, 2021	983
Identification of compensable data	2,251	Not available at this time	April 1, 2021	2,343
Amendment of registration – data required, label changes	1,506	Not available at this time	April 1, 2021	1,568
Amendment of registration – data required, other	1,206	Not available at this time	April 1, 2021	1,256
Processing	1,180	Not available at this time	April 1, 2021	1,229

Fee grouping	Fees to be Paid for the Examination of an Application in Respect of a Pest Control Product				
Fee	Category L Component Based 240 Days of Review (Equivalency and data compensation assessment of end-use product and manufacturing concentrate with partial data package - microbials and straight chain lepidopteran pheromone)				
Fee-setting authority	 <u>Pest Control Products Act</u> xvi <u>Pest Control Products Fees and Charges Regulations</u> xvii 				
Year fee-setting authority was introduced	1997				
Last year fee-setting authority was amended	2017				
Service standard	240 Days of Review				
Performance result	N/A (0 applications completed in 2019-20)				
Application of Low- Materiality Fees Regulations	Material (>\$151): All fees				
Foo	2040 20 for 2040 20 For Adjusted for				

Fee	2019–20 fee amount (\$)	2019–20 total fee revenue (\$)	Fee adjustment date	Adjusted fee amount in 2021–22 (\$)
Identification of compensable	2,251	Not available		2,343
data		at this time	April 1, 2021	
Amendment of registration –	1,506	Not available	April 1, 2021	1,568
data required, label changes		at this time		
Amendment of registration –	1,206	Not available	April 1, 2021	1,256
data required, other		at this time		
Amendment of registration	302	Not available	April 1, 2021	316
		at this time		
Processing	1,180	Not available	April 1, 2021	1,229
		at this time		

Fee grouping	Fees to be Paid for the Examination of an Application in Respect of a Pest Control Product
Fee	Category L Component Based – Applications with atypical timelines (Tailgaters, renegotiated timelines, synchronized timelines, coordination with Re-Evaluation)
Fee-setting authority	 <u>Pest Control Products Act</u> xvi <u>Pest Control Products Fees and Charges Regulations</u> xvii
Year fee-setting authority was introduced	1997
Last year fee-setting authority was amended	2017
Service standard	Variable as per Management of Submission Policy ^{xviii} , Appendix I, Table 7
Performance result	100% (1/1 applications met the service standard)
Application of Low- Materiality Fees Regulations	Material (>\$151): All fees

Fee	2019–20 fee amount (\$)	2019–20 total fee revenue (\$)	Fee adjustment date	Adjusted fee amount in 2021–22 (\$)
Product Chemistry – active ingredient	5,071	Not available at this time	April 1, 2021	5,277
Product Chemistry – end-use product or manufacturing concentrate	2,824	Not available at this time	April 1, 2021	2,939
Toxicology data accompanying an application to register a pest control product –or to amend a pest control product –that contains an registered active ingredient	16,470	Not available at this time	April 1, 2021	17,136
Toxicology data-acute toxicity studies	3,075	Not available at this time	April 1, 2021	3,200
Exposure data - other	5,426	Not available at this time	April 1, 2021	5,646
Metabolism data	30,113	Not available at this time	April 1, 2021	31,331
Residue data	16,479	Not available at this time	April 1, 2021	17,146
Environmental fate data - other	12,013	Not available at this time	April 1, 2021	12,500
Environmental toxicology data – other	2,566	Not available at this time	April 1, 2021	2,671

Fee	2019–20 fee amount (\$)	2019–20 total fee revenue (\$)	Fee adjustment date	Adjusted fee amount in 2021–22 (\$)
Value and effectiveness data for a pest control product	944	Not available at this time	April 1, 2021	983
Identification of compensable data	2,251	Not available at this time	April 1, 2021	2,343
Amendment of registration – data required, label changes	1,506	Not available at this time	April 1, 2021	1,568
Amendment of registration – data required, other	1,206	Not available at this time	April 1, 2021	1,256
Amendment of registration	302	Not available at this time	April 1, 2021	316
Processing	1,180	Not available at this time	April 1, 2021	1,229

Annual Charge (for a registered Pest Control Product)

A registrant must pay each year, in respect of every pest control product that is registered in their name on April 1 of the year, an annual charge. All registered products including technical grade active ingredients (TGAI), import for manufacturing and export program (IMEPs), private label products and master copies must pay the annual charge.

Fee grouping	Annual	Charge (for a rec	istered Pest Co	ntrol Product)	
Fee		Charge		,	
Fee-setting authority	•	Pest Control Pro		Charges Regula	ations ^{xvii}
Year fee-setting authority was introduced	1997				
Last year fee-setting authority was amended	2017				
Service standard	100% of all invoices were issued by April 30 th 2019				
Performance result	100%				
Application of Low- Materiality Fees Regulations	Materia	al (>\$151): All fee	S		
Fee		2019–20 fee amount (\$)	2019–20 total fee revenue (\$)	Fee adjustment date	Adjusted fee amount in 2021–22 (\$)
Annual Charge		The lesser of \$3,679.20 and 4% of the actual gross revenue during the registrant's preceding fiscal year, but not less than \$100	8,654,696	April 1, 2021	The lesser of \$3,745.27 and 4% of the actual gross revenue during the registrant's preceding fiscal year, but not less than \$100

Fees Charged for Filing a Claim for Exemption under the Hazardous Materials Information Review Act

When a supplier or employer wants to be exempt from having to disclose confidential business information (CBI), such as the chemical identity of one or more trade-secret hazardous ingredients, they must file a claim for exemption with Health Canada.

Fee grouping	Fees C	Charged for Filing	a Claim for Exer	nption under the	Hazardous
	Materia	Materials Information Review Act			
Fee	•	Original Claims			
	•	Refiled Claims			
		A 50% fee reduction	on is available fo	or small business	ses that meets
	certain	criteria			
Fee-setting	•	Hazardous Mate	erials Information	Review Act xix	
authority	•	<u>Hazardous Mate</u>	erials Information	n Review Regula	ntions xx
Year fee-setting	1988				
authority was					
introduced Last year	2002				
fee-setting	2002				
authority was					
amended					
Service standard		calendar days fro			mplete
		application, for the issuance of a registry number			
Performance result		f claims (original a	ind refiled) were	registered within	n the service
Application of Low-	standa	rd of seven days			
Materiality Fees	Materia	al (> \$151): All fee	oc.		
Regulations	Widtoni	αι (* Ψ101). 7 tti 100			
Fee		2019-20 fee	2019–20	Fee	Adjusted fee
		amount (\$)	total fee	adjustment	amount in
Onimin at Ole to a few to 4	<u></u>	4 000 00	revenue (\$)	date	2021–22 (\$)
Original Claim (up to 1		1,839.60 408.80	Not available	April 1, 2021	1,872.64
25)	Original Claim (between 16-25)		at this time	April 1, 2021	416.14
Original Claim (26+)	Original Claim (26+)			April 1, 2021	208.07
Refiled Claims (up to 15)		1,471.68	Not available	April 1, 2021	1,498.11
Refiled Claims (between	en 16-	327.04	at this time	April 1, 2021	332.91
25) Refiled Claims (26+)		163.52		April 1, 2021	166.46
Nemeu Claims (20+)		103.32		Apili 1, 2021	100.40

Cannabis Fees

Fees are charged for the following transactional activities: application screening, security clearances, and import/export permits. In addition, an Annual Regulatory Fee is charged which covers costs associated with a range of regulatory activities including regulatory inspections, compliance and enforcement, program management and oversight. These activities are carried out by Health Canada, the Canada Border Services Agency, the Public Health Agency of Canada and Public Safety Canada to support the objectives of the *Cannabis Act* with respect to the legislation and regulations of cannabis.

Fee grouping	Canna	bis Fees			
Fee	Licenc	e Application Scre	ening Fees		
Fee-setting	•	Cannabis Act xxi			
authority		Cannabis Fees	Order ^{xxii}		
	- Cannable Feed Order				
Year fee-setting					
authority was	2018				
introduced					
Last year					
fee-setting	Not Ap	plicable			
authority was					
amended	11 10	<u> </u>		P. 1.1.1	
Service standard					tive service standard
		usiness-days for			ation from applicants.
Performance result		n-binding adminis			
Application of <i>Low-</i>	THETE	n-binding adminis	strative standard	was met 7070 0	i die dille.
Materiality Fees	Not su	bject to Service F	ees Act		
Regulations		.,			
Fee		2019-20 fee	2019–20	Fee	Adjusted fee
		amount (\$)	total fee	adjustment	amount in 2021-22
			revenue (\$)	date	(\$)
Licence Application		1,675	No data	April 1, 2021	1,706
Screening Fee - Liceno	ce for		available at		
micro-cultivation		0.050	this time	A !! 4 . 0004	0.444
Licence Application Screening Fee - Licence	oo for	3,350	No data available at	April 1, 2021	3,411
standard cultivation	Se IOI		this time		
Licence Application		1,675	No data	April 1, 2021	1,706
Screening Fee - Licena	ce for	1,010	available at	7.0 1, 2021	1,100
a nursery	_		this time		
Licence Application		1,675	No data	April 1, 2021	1,706
Screening Fee - Liceno			available at		
micro-processing			this time		
• •	icence Application Screening 3,350		No data	April 1, 2021	3,411
	Fee - Licence for standard		available at		
processing		0.050	this time	A	0.444
Licence Application	f	3,350	No data	April 1, 2021	3,411
Screening Fee - Licena			available at		
sale for medical purpos	ses		this time		

Fee grouping	Cannal	ois Fees			
Fee	Application for a security Clearance				
Fee-setting authority	 <u>Cannabis Act</u> xxi <u>Cannabis Fees Order</u> xxii 				
Year fee-setting authority was introduced	2018				
Last year fee-setting authority was amended	Not Applicable				
Service standard	No administrative service standard for this fee as outlined during the 2018 consultation on the Proposed Approach to Cost Recovery for the Regulation of Cannabis and the subsequent Regulatory Impact Analysis Statement for the <i>Cannabis Fees Order</i> .				
Performance result	Not ap	olicable			
Application of Low- Materiality Fees Regulations	Not subject to Service Fees Act				
Fee	2019–20 fee amount (\$)		2019–20 total fee revenue (\$)	Fee adjustment date	Adjusted fee amount in 2021–22 (\$)
Application for a secur Clearance	-		No data available at this time	April 1, 2021	1,722

Fee grouping	Cannal	bis Fees			
Fee	Application for import or export permit				
Fee-setting authority	•	Cannabis Act xxi Cannabis Fees	<u>Order ^{xxii}</u>		
Year fee-setting authority was introduced	2018	2018			
Last year fee-setting authority was amended	Not Applicable				
Service standard	Health Canada commits to a non-binding administrative service standard of 30 business days from the date that payment is received for the application to the issuance or rejection of the permit. The standard excludes time spent awaiting additional information from applicants.			t is received nit. The	
Performance result	The no	n-binding adminis	strative standard	was met 82.469	% of the time.
Application of Low- Materiality Fees Regulations	Not subject to Service Fees Act				
Fee	2019–20 fee amount (\$)		2019–20 total fee revenue (\$)	Fee adjustment date	Adjusted fee amount in 2021–22 (\$)
Application for import of export permit	or	624	No data available at this time	April 1, 2021	636

Fee grouping	Cann	abis Fees			
Fee	Annu	al Regulatory Fee)		
Fee-setting authority	•	Cannabis Act ' Cannabis Fees			
Year fee-setting authority was introduced	2018				
Last year fee-setting authority was amended	Not A	pplicable			
Service standard	No administrative service standard for this fee as outlined during the 2018 consultation on the Proposed Approach to Cost Recovery for the Regulation of Cannabis and the subsequent Regulatory Impact Analysis Statement for the <i>Cannabis Fees Order</i> .				
Performance result	Not a	pplicable			
Application of Low- Materiality Fees Regulations	Not subject to Service Fees Act				
Fee		2019–20 fee amount (\$)	2019–20 total fee revenue (\$)	Fee adjustment date	Adjusted fee amount in 2021–22 (\$)
Annual fee - Licence for micro-cultivation Annual fee - Licence for standard cultivation Annual fee - Licence for nursery Annual fee - Licence for micro-processing Annual fee - Licence for standard processing Annual fee - Licence for standard processing Annual fee - Licence for sale for medical purpose	or a or or	<u>as per</u> <u>Cannabis</u> <u>Fees Order</u> ^{xxii}	No data available at this time	Exempt	<u>as per</u> <u>Cannabis</u> <u>Fees Order</u> ^{xxii}

National Dosimetry Products and Services Fees

National Dosimetry Services (NDS) provides radiation monitoring services to Canadians who are exposed to radiation in their work environment. NDS provides commercial dosimetry services to over 100,000 individuals working in over 12,500 organizations and operates on a cost-recovery basis. There are a number of components to NDS that will be billed on a regular basis. These fees include the annual support fee, the shipping and handling fee and the processing fee. Other fees are billed depending on whether additional services are requested or if a dosimeter is overdue, late, lost or damaged.

-	N				
Fee grouping	National Dosimetry Products and Services Fees				
Fee	National Dosimetry Products and Services Fees				
Fee-setting authority	Ministerial Authority to Enter into Contract				
Year fee-setting authority	2004				
was introduced					
Last year fee-setting	2017				
authority was amended					
Service standard	Provide timely, responsive and reliable dosimetry services: 1) Exposures reported to the National Dose Registry within 45 calendar days of receipt (a regulatory standard set by the Canadian Nuclear Safety Commission (CNSC)); 2) Dosimeters shipped 10 to 13 working days prior to exchange date with clients; 3) Dose results for whole body and extremity services reported to clients within internal service standards of 20 to 30 business days, depending on the dosimetry service; 4) Client account information updated within two business days; 5) Client voice mails responded to within one business day; and 6) Client emails responded to within two business days.				
Performance result	1) 100% compliance with the 45 day CNSC regulatory				
r errormance result	standard;				
	 Shipped out 99.97% of dosimeters 10 to 13 working days prior to exchange date; 99.7% reported within the 20 to 30 business day internal standard, depending on the dosimetry service; 97% completed within two business days; 94% being addressed within one business day; and 93% addressed within two business days. 				
Application of Low- Materiality Fees Regulations	Not subject to section 17 of the Service Fees Act				

Fee	2019–20 fee amount (\$)	2019–20 total fee revenue (\$)	Fee adjustment date	Adjusted fee amount in 2021–22 (\$)			
Core Fees:							
Annual support	80.00	Not available at this time	April 1, 2021	82.50			
Annual support — multi- group discount (5+ groups)	50.00	Not available at this time	n/a	50.00			
Shipping and handling (per shipment)	14.50	Not available at this time	n/a	14.50			
Processing fees (per dosimeter	5.00 to 17.50	Not available at this time	April 1, 2021	5.25 to 17.50			
Additional Fees:							
Ad hoc dosimeter request — add-on (per shipment)	65.00	Not available at this time	n/a	65.00			
Priority processing request (per request)	95.00	Not available at this time	n/a	95.00			
Pregnancy service (semi- monthly)	375.00	Not available at this time	n/a	375.00			
Electronic personal dosimeter rental (per year)	415.00	Not available at this time	n/a	415.00			
Specialized consultation (per hour)	125.00	Not available at this time	n/a	125.00			
Customized reporting (per hour)	60.00	Not available at this time	n/a	60.00			
NDR dose modifications (per hour)	60.00	Not available at this time	n/a	60.00			
Reprinting reports (per report)	10.00	Not available at this time	n/a	10.00			
Overdue dosimeter (three months after wearing period ends)	55.00	Not available at this time	n/a	55.00			
Late dosimeter (six months after wearing period ends	55.00	Not available at this time	n/a	55.00			
Lost/damaged dosimeter	82.50	Not available at this time	n/a	82.50			
Damaged electronic personal dosimeter	415.00	Not available at this time	n/a	415.00			
Credit upon returning overdue dosimeter	28.75	Not available at this time	n/a	28.75			
Credit upon returning late or lost dosimeter	57.50	Not available at this time	n/a	57.50			

Master File Fees

A Master File (MF) is a reference that provides information about specific processes or components used in the manufacturing, processing, or packaging of a drug. The MF is a useful vehicle for providing information to Health Canada, where that information is confidential business information (CBI) and is not available to the manufacturer of the dosage form or to the sponsors of a drug submission, DIN (Drug identification Number) application or clinical trial application (CTA).

Fee grouping	Master File Fees					
Fee	 New Master Files (file registration) Drug Master Files - letter of access Drug Master Files - Update 					
Fee-setting authority	Ministerial Authority to Enter into Contract					
Year fee-setting authority was introduced	1996					
Last year fee-setting authority was amended	2017					
Service standard	30 calendar days					
Performance result	99.86% issued within 30 calendar days					
Application of Low- Materiality Fees Regulations	Not subject to section 17 of the Service Fees Act					
Fee		2019–20 fee amount (\$)	2019–20 total fee revenue (\$)	Fee adjustment date	Adjusted fee amount in 2021–22 (\$)	
New Master Files (file registration)		1,248	Not available at this time	April 1, 2021	1,298	
Drug Master Files – letter of access		176	Not available at this time	April 1, 2021	184	
Drug Master Files - Update		541	Not available at this time	April 1, 2021	563	

Certificate of Pharmaceutical Product Fee

A certificate issued establishing the status of the pharmaceutical, biological, radiopharmaceutical or veterinary product listed and the Good Manufacturing Practice status of the fabricator of the product.

Fee grouping	Certificate of Pharmaceutical Product Fee					
Fee	Certificate of Pharmaceutical Product					
Fee-setting authority	Ministerial Authority to Enter into Contract					
Year fee-setting authority was introduced	1996					
Last year fee-setting authority was amended	Not applicable					
Service standard	10 calendar days to issue certificate					
Performance result	87% of certificates issued within 10 calendar days					
Application of Low- Materiality Fees Regulations	Not subject to section 17 of the Service Fees Act					
Fee		2019–20 fee amount (\$)	2019–20 total fee revenue (\$)	Fee adjustment date	Adjusted fee amount in 2021–22 (\$)	
Certificate of Pharmaceutical Product		90	263,554	April 1, 2021	94	

Endnotes

ⁱ Service Fees Act, https://laws-lois.justice.gc.ca/eng/acts/S-8.4/index.html

ii Directive on Charging and Special Financial Authorities, https://www.tbs-sct.gc.ca/pol/doc-eng.aspx?id=32502

iii Cannabis for Medical Purposes Remission Order, https://www.tbs-sct.gc.ca/pol/doc-eng.aspx?id=32502

iv Order Amending the Cannabis Fees Order (Exemptions — Sale for Medical Purposes), http://www.gazette.gc.ca/rp-pr/p2/2020/2020-01-22/html/sor-dors8-eng.html

^v Financial Administration Act, https://laws-lois.justice.gc.ca/eng/acts/f-11/

vi Fees in Respect of Drugs and Medical Devices Regulations, https://laws-lois.justice.gc.ca/eng/acts/f-11/

vii Food and Drugs Act, https://laws-lois.justice.gc.ca/eng/acts/f-27/

viii Fees in Respect of Drugs and Medical Devices Order, https://laws-lois.justice.gc.ca/eng/regulations/SOR-2019-124/FullText.html

ix Authority to Sell Veterinary Drugs Fees Regulations, https://laws-lois.justice.gc.ca/eng/regulations/sor-95-31/20110401/P1TT3xt3.html

^x Patent Act, https://laws-lois.justice.gc.ca/eng/acts/p-4/index.html

xi Certificate of Supplementary Protection Regulations, https://laws-lois.justice.gc.ca/eng/regulations/SOR-2017-165/FullText.html

xii Veterinary Drug Evaluation Fees Regulations, https://laws-lois.justice.gc.ca/eng/regulations/sor-96-143/20060322/P1TT3xt3.html

xiii Establishment Licensing Fees (Veterinary Drugs) Regulations, https://laws-lois.justice.gc.ca/eng/regulations/sor-98-4/page-1.html

xiv Fees in Respect of Dealer's Licences Regulations, https://laws-lois.justice.gc.ca/eng/regulations/sor-2011-79/page-1.html

xv Licensed Dealers for Controlled Drugs and Narcotics (Veterinary Use) Fees Regulations, https://laws-lois.justice.gc.ca/eng/regulations/SOR-98-5/page-1.html

xvi Pest Control Products Act, https://laws-lois.justice.gc.ca/eng/acts/p-9.01/

xvii Pest Control Products Fees and Charges Regulations, https://laws-lois.justice.gc.ca/eng/regulations/SOR-2017-9/page-1.html#docCont

xviii Management of Submissions Policy, https://www.canada.ca/en/health-canada/services/consumer-product-safety/reports-publications/pesticides-pest-management/policies-guidelines/regulatory-directive/2017/dir2017-01-management-submissions-policy.html

xix Hazardous Materials Information Review Act, https://laws-lois.justice.gc.ca/eng/acts/H-2.7/

xx Hazardous Materials Information Review Regulations, https://laws-lois.justice.gc.ca/eng/regulations/sor-88-456/

xxi Cannabis Act, https://laws-lois.justice.gc.ca/eng/acts/c-24.5/

xxii Cannabis Fees Order, https://laws-lois.justice.gc.ca/eng/regulations/SOR-2018-198/page-1.html